{"gene":"ESR2","run_date":"2026-04-28T17:46:03","timeline":{"discoveries":[{"year":1996,"finding":"ESR2 (ERβ) was identified as a novel estrogen receptor with high conservation in the DNA-binding domain (96%) and ligand-binding domain (58%) relative to ERα. Ligand-binding experiments confirmed 17β-estradiol binding, and transient transfection with an ERE-based reporter demonstrated estradiol-dependent transactivation. ICI-164384 (ERα antagonist) also antagonizes ERβ.","method":"Degenerate PCR cloning, ligand-binding assay, transient transfection/reporter assay","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 1-2 — original cloning with functional validation by ligand binding and transactivation assay; foundational paper >1800 citations","pmids":["8769313"],"is_preprint":false},{"year":1997,"finding":"The human ESR2 gene was mapped to a distinct chromosomal locus from ESR1, confirming two independent ER genes exist in humans. ESR2 is expressed in multiple tissues including ovarian granulosa cells and developing spermatids of the testis.","method":"Genomic cloning, chromosomal localization, Northern blot, in situ hybridization","journal":"The Journal of clinical endocrinology and metabolism","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (genomic mapping, expression analysis) in foundational gene characterization paper","pmids":["9398750"],"is_preprint":false},{"year":1998,"finding":"Multiple ESR2 (ERβ) isoforms (ERβ1–5) were identified, all diverging within the predicted helix 10 of the ligand-binding domain due to differential exon usage. In vitro band-shift studies showed isoforms form DNA-binding homodimers and heterodimers with each other and with ERα.","method":"cDNA library screening, RT-PCR, in vitro gel-shift (EMSA)","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1-2 — reconstitution of DNA-binding complexes by EMSA combined with molecular cloning; replicated independently","pmids":["9636657"],"is_preprint":false},{"year":1998,"finding":"Full-length human ESR2 (hERβ) was cloned from testis, encoding 53 additional N-terminal amino acids. ERα–ERβ protein interaction was demonstrated in vitro by GST pull-down assay and in vivo by co-immunoprecipitation, showing that ERα and ERβ can interact and cross-signal each other.","method":"cDNA cloning, GST pull-down assay, co-immunoprecipitation","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1-2 — reciprocal in vitro and in vivo interaction assays confirming ERα/ERβ heterodimerization","pmids":["9473491"],"is_preprint":false},{"year":1998,"finding":"A novel ESR2 isoform, ERβcx, was identified that lacks ligand-binding ability (Kd unmeasurable vs ERβ Kd ~0.6 nM for E2), cannot bind ERE in gel-shift assays, and preferentially heterodimerizes with ERα rather than ERβ, acting as a dominant negative inhibitor of ERα transactivation.","method":"Molecular cloning/alternative splicing characterization, ligand-binding assay, EMSA, transient transfection/reporter assay","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal biochemical assays (binding, EMSA, transactivation) demonstrating dominant-negative mechanism","pmids":["9671811"],"is_preprint":false},{"year":1999,"finding":"ERβ contains a functional AF-2 domain but lacks a strong AF-1; instead its N-terminus harbors a repressor domain. ERβ functions as a transdominant inhibitor of ERα transcriptional activity at subsaturating hormone levels by forming ERα/ERβ heterodimers. ERβ abolishes the partial agonist activity of tamoxifen observed through ERα and decreases overall cellular sensitivity to estradiol. ERβ also interacts with target gene promoters in a ligand-independent manner.","method":"Domain deletion/chimeric receptor analysis, transient transfection/reporter assay, co-immunoprecipitation (heterodimer detection), chromatin binding assay","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods including mutagenesis and co-IP; highly cited foundational mechanistic study","pmids":["10579320"],"is_preprint":false},{"year":2000,"finding":"The activated dioxin receptor (AhR/Arnt heterodimer) directly associates with both ERα and ERβ. This association recruits unliganded ER and co-activator p300 to estrogen-responsive gene promoters, activating transcription. Oestrogenic actions of AhR agonists were absent in AhR−/− or ERα−/− ovariectomized mice, establishing the molecular mechanism by which dioxins exert estrogenic effects through ER.","method":"Co-immunoprecipitation, chromatin immunoprecipitation, reporter assay, knockout mouse model","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods including in vivo KO validation; highly cited mechanistic study","pmids":["12774124"],"is_preprint":false},{"year":2000,"finding":"In BERKO (ERβ knockout) mice, the immature uterus shows elevated progesterone receptor and Ki-67 levels and exaggerated responsiveness to 17β-estradiol, including enlarged lumen, increased secretion, and enhanced induction of VEGF, IGF-1, complement C3, and IL-1β. E2 failed to downregulate PR in the luminal epithelium of BERKO mice. These findings establish ERβ as a modulator of ERα activity and as having an antiproliferative function in the uterus.","method":"ERβ knockout mouse model, immunohistochemistry, ELISA, quantitative gene expression","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — loss-of-function mouse model with multiple specific molecular phenotypic readouts","pmids":["10823946"],"is_preprint":false},{"year":2000,"finding":"ERβ and ERα physically interact with Sp1 protein (demonstrated by co-immunoprecipitation and pull-down assays) and bind preferentially to the C-terminal region of Sp1. ERβ/Sp1-mediated transcriptional activation at GC-rich promoter elements is ligand- and cell-context-dependent. Domain-swap experiments showed the ERα AF-1 domain (aa 79–117) is specifically required for activation at Sp1 elements, independently of ER subtype context.","method":"Co-immunoprecipitation, GST pull-down, chimeric receptor/deletion analysis, luciferase reporter assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — reconstitution of ER-Sp1 complex with domain mutagenesis and functional validation","pmids":["10681512"],"is_preprint":false},{"year":2000,"finding":"ERβ, when expressed in androgen receptor (AR)-positive LNCaP prostate cancer cells, associates with AR and Src upon steroid stimulation, triggering the Src/Raf-1/Erk-2 pathway. Src SH3 domain interacts with a proline-rich stretch of AR; Src SH2 domain interacts with phosphotyrosine 537 of ERα (and analogous site of ERβ). Microinjection of dominant-negative Src abolishes steroid-stimulated S-phase entry, demonstrating that steroid-receptor/Src complexes are required for proliferative signaling.","method":"Co-immunoprecipitation, GST fusion pull-down, microinjection of dominant-negative constructs, BrdU S-phase entry assay","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1-2 — reconstitution of protein complex with functional mutagenesis and microinjection rescue; highly cited","pmids":["11032808"],"is_preprint":false},{"year":2001,"finding":"ERβ expressed via adenoviral vector in ER-negative MDA-MB-231 breast cancer cells localizes to the nucleus, transactivates ERE reporter constructs in the presence of E2, and inhibits cell proliferation in a ligand-independent manner. ERβ (unlike ERα) cannot regulate c-myc expression but induces p21 (CDKN1A). Both ERα and ERβ decrease cell motility and invasion.","method":"Adenoviral overexpression, immunocytochemistry, RT-PCR, Western blot, proliferation assay, invasion assay, reporter assay","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 2 — direct gain-of-function in defined cell system with multiple orthogonal readouts","pmids":["11517191"],"is_preprint":false},{"year":2002,"finding":"ERβ opposes ERα at the cyclin D1 promoter: ERα activates cyclin D1 gene transcription via both a CRE element at −57 and an AP-1 site at −954, while ERβ inhibits cyclin D1 expression in the presence of estrogens (activates only with antiestrogens). ERβ completely dominates over ERα or superactive ERαK206A in blocking estrogen/ERα-mediated cyclin D1 induction.","method":"Luciferase reporter assay with CRE/AP-1 site mutants, Western blot for endogenous cyclin D1, chimeric receptor analysis in HeLa cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — promoter dissection with mutagenesis and endogenous protein validation; highly cited","pmids":["11986316"],"is_preprint":false},{"year":2003,"finding":"ERβ is essential for late embryonic brain development. ERβ knockout mice show smaller brains at E18.5 with fewer cortical neurons. BrdU labeling experiments demonstrated a defect in neuronal migration (fewer BrdUrd-labeled cells in superficial cortical layers by E18.5/P14 when labeled at E14.5–E16.5) and increased apoptosis in the ventricular zone. Radial glia processes guiding migrating neurons were fragmented in ERβ-null mice.","method":"ERβ knockout mouse model, BrdU birth-dating/migration assay, TUNEL apoptosis assay, immunofluorescence of radial glia","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — genetic KO with multiple orthogonal assays establishing specific mechanistic defects in neuronal migration and survival","pmids":["12515851"],"is_preprint":false},{"year":2004,"finding":"ERβ expression in ERα-positive MCF-7 breast cancer cells causes G2 cell cycle arrest and inhibits tumor formation in mouse xenografts. ERβ represses transcription of c-myc, cyclin D1, and cyclin A, while increasing p21(Cip1) and p27(Kip1). This is opposite to ERα, which promotes proliferation and tumor formation.","method":"Adenoviral ERβ expression, flow cytometry (cell cycle), mouse xenograft model, RT-PCR/Western blot for cell cycle genes","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — gain-of-function with in vivo xenograft validation and defined molecular mechanism; highly cited","pmids":["14729654"],"is_preprint":false},{"year":2004,"finding":"Induced ERβ expression in T47D breast cancer cells reduces 17β-estradiol-stimulated proliferation when ERβ mRNA equals ERα levels. ERβ decreases cyclin E, Cdc25A, p45(Skp2), reduces Cdk2 kinase activity, and increases p27(Kip1), suggesting ERβ acts on the G1-phase cell-cycle machinery to oppose ERα-driven proliferation.","method":"Inducible ERβ expression system, proliferation assay, Western blot, Cdk2 kinase activity assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — inducible expression with kinase activity assay and defined cell-cycle pathway placement","pmids":["14745018"],"is_preprint":false},{"year":2004,"finding":"ERβ localizes primarily to mitochondria, not to the nucleus, in rat primary neurons, primary cardiomyocytes, and a murine hippocampal cell line. This was established by immunocytochemistry with two independent ERβ antibodies co-localized with mitochondrial markers, immunoblotting of purified human heart mitochondria, and mass spectrometric identification of seven ERβ tryptic fragments in the mitochondrial fraction. No nuclear translocation of ERβ occurred upon 17β-estradiol treatment.","method":"Immunocytochemistry, confocal microscopy, subcellular fractionation, immunoblotting of purified mitochondria, MALDI mass spectrometry","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods including proteomics and purified organelle fractionation; highly cited","pmids":["15024130"],"is_preprint":false},{"year":2006,"finding":"ERβ isoforms 2, 4, and 5 do not bind ligand with full activity, cannot form homodimers, and have no innate transcriptional activity due to structural differences in their C-terminus (disrupted helix 12). However, they can heterodimerize with ERβ1 and enhance ERβ1 transactivation in a ligand-dependent manner. ERβ1 is the obligatory active partner; a single functional helix 12 in a dimer is sufficient for gene transactivation. ERβ1 preferentially forms heterodimers with other isoforms under estrogen (but not phytoestrogen) stimulation.","method":"Molecular modeling, co-immunoprecipitation (dimerization), luciferase reporter assay, ligand-binding assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 — structural modeling validated by functional assays showing isoform-specific dimerization and transactivation","pmids":["16938840"],"is_preprint":false},{"year":2007,"finding":"Activation of ESR2 (ERβ) in vivo by the selective agonist 8β-VE2 in ovariectomized spontaneously hypertensive rats lowers systolic blood pressure (−38 mmHg), reduces peripheral vascular resistance, enhances aortic ERβ expression, improves NO-dependent vasorelaxation, augments phosphorylation of vasodilator-stimulated phosphoprotein in isolated aortic rings, and attenuates cardiac hypertrophy without uterotrophic effects.","method":"In vivo pharmacological agonist administration, echocardiography, vascular ring relaxation assay, Western blot, immunohistochemistry","journal":"Cardiovascular research","confidence":"Medium","confidence_rationale":"Tier 2 — selective ERβ agonist in vivo with multiple functional cardiovascular readouts; single lab","pmids":["18056768"],"is_preprint":false},{"year":2007,"finding":"AP-2α and AP-2γ (but not AP-2β) regulate ESR2 transcription by binding to the 0N promoter at a methylation hotspot (center 1, a 16-bp AP-2 binding site). ChIP confirmed AP-2α occupancy. Forced AP-2α/γ expression increased ERβ mRNA; siRNA knockdown reduced it. ERβ transcript levels correlate with AP-2α/γ levels across PCa cell lines.","method":"Chromatin immunoprecipitation (ChIP), promoter deletion/reporter assay, siRNA knockdown, RT-PCR, forced expression","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1-2 — ChIP plus mutagenesis plus siRNA plus forced expression establishes ESR2 as AP-2-regulated gene","pmids":["17525739"],"is_preprint":false},{"year":2008,"finding":"ERβ inhibits ERα-mediated induction of progesterone receptor in the neonatal rat ventromedial nucleus of the hypothalamus in an anatomically specific manner. Selective ERα activation in the relative absence of ERβ induces greater PR expression; selective ERβ activation attenuates this ERα-mediated increase in the ventromedial nucleus but not the medial preoptic nucleus, despite high ERα expression in both regions.","method":"Selective ER agonist administration in vivo, in situ hybridization/immunohistochemistry for PR as functional readout","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 — selective agonists with anatomically resolved functional readout; single lab","pmids":["18511514"],"is_preprint":false},{"year":2009,"finding":"The selective ERβ agonist ERB-041 inhibits LPS-induced iNOS expression in peritoneal macrophages from endometriosis patients by preventing nuclear translocation of NF-κB p65, without affecting the ERK pathway. ERβ (not ERα) is the predominant ER subtype in these macrophages. ERKs are involved in LPS-induced iNOS but are not repressed by ERβ activation.","method":"RT-PCR, immunoblot, pharmacological agonist treatment, nuclear fractionation (NF-κB translocation), ERK inhibitor (U0126)","journal":"Molecular immunology","confidence":"Medium","confidence_rationale":"Tier 2 — selective agonist with pathway dissection using inhibitors; single lab, moderate evidence","pmids":["19447495"],"is_preprint":false},{"year":2005,"finding":"Com-1/P8 protein physically interacts with ERβ in breast cancer cells as demonstrated by reciprocal co-immunoprecipitation. Both proteins co-localize in the nucleus. 17β-estradiol stimulation reduces nuclear Com-1 staining, and this reduction is reversed by ubiquitin/proteasome inhibitors (ubiquitin aldehyde, lactacystin), indicating that the ubiquitin-proteasome pathway regulates the Com-1/ERβ complex. Elimination of Com-1 leads to increased estradiol-stimulated growth in ER-negative/ERβ-positive cells.","method":"Reciprocal co-immunoprecipitation, immunocytochemistry, proteasome inhibitor treatment, ribozyme transgene knockdown, proliferation assay","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 3 — reciprocal Co-IP plus functional assay; single lab","pmids":["15781258"],"is_preprint":false},{"year":2016,"finding":"In adult male rats, ESR2-selective agonist administration reduces sperm counts due to spermiation failure (defects in tubulobulbar complex formation caused by decreased expression of actin remodeling genes) and increased spermatocyte apoptosis associated with elevated oxidative stress and decreased anti-apoptotic gene transcripts. ESR1 agonist causes arrest of round-to-elongated spermatid differentiation. The two receptors regulate distinct aspects of spermatogenesis.","method":"In vivo selective ESR agonist administration, histology, gene expression analysis, sperm count, oxidative stress assay","journal":"Molecular and cellular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 — selective receptor agonists in vivo with multiple cellular and molecular readouts distinguishing ESR1 vs ESR2 roles","pmids":["27004961"],"is_preprint":false},{"year":2017,"finding":"E2/ERβ suppresses ISO-induced cardiac cellular hypertrophy in H9c2 cardiomyoblasts by inhibiting Ca2+-calcineurin signaling. ERβ overexpression and/or E2 inhibits ISO-induced elevation of p-CaMKII, calcineurin, p-GATA4, NFATc3, ANP, and BNP. Mechanistically, E2/ERβ suppresses Ca2+ influx, inhibits calcineurin activity to activate I-1 protein, suppresses PP1, then induces PLB phosphorylation and activation, resulting in Ca2+ reuptake into the sarcoplasmic reticulum. NFATc3 nuclear translocation is also inhibited. Calcineurin inhibitor (CsA) confirmed calcineurin as key mediator; Ca2+ chelator (BAPTA) blocked E2/ERβ effects.","method":"ERβ overexpression, calcineurin inhibitor (CsA), Ca2+ chelator (BAPTA), Western blot for signaling cascade proteins, immunofluorescence (NFATc3 localization), cell size measurement","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — pathway dissection with pharmacological inhibitors and overexpression; single lab, multiple mechanistic readouts","pmids":["28863192"],"is_preprint":false},{"year":2018,"finding":"ESR2 is required for gonadotropin-induced follicle maturation and ovulation in rats. RNA-seq of granulosa cells from Esr2-null and Esr2-DBD mutant rats identified 1,696 differentially expressed genes enriched in steroidogenesis, follicle maturation, and ovulation pathways. Kiss1 was identified as a key ESR2-regulated gene in granulosa cells, indicating an intra-follicular role distinct from hypothalamic Kiss1 regulation by ESR1.","method":"Esr2-null and DNA-binding domain mutant rat models, RNA-sequencing of granulosa cells, molecular pathway analysis, exogenous gonadotropin stimulation","journal":"Molecular and cellular endocrinology","confidence":"High","confidence_rationale":"Tier 2 — two genetic models (null and DBD mutant) with genome-wide transcriptome in specific cell type","pmids":["29580824"],"is_preprint":false},{"year":2018,"finding":"ESR2 directly regulates Kiss1 expression in granulosa cells. The Kiss1 promoter, upstream enhancer, and downstream enhancer possess conserved EREs with active histone marks in gonadotropin-stimulated granulosa cells. ChIP revealed ESR2 binding enrichment at these regulatory regions. ERE mutation in the Kiss1 promoter blocked ESR2-mediated induction. Gonadotropins induce ERK2-mediated ESR2 phosphorylation and upregulate AP-1 factors (FOSL2, JUNB), which synergistically activate the Kiss1 promoter with ESR2.","method":"ChIP, ERE mutagenesis/reporter assay, ESR2 overexpression, kinase activity assay (ERK2-ESR2 phosphorylation), immunoblot, PMSG/hCG gonadotropin stimulation","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 1-2 — ChIP, mutagenesis, and phosphorylation assay establishing ESR2-ERE-AP1 co-regulation of Kiss1","pmids":["30277501"],"is_preprint":false},{"year":2017,"finding":"Biallelic (c.541_543del p.Asn181del, in the DNA-binding domain) and monoallelic (p.Gly84Val in N-terminus; p.Leu426Arg in ligand-binding domain) ESR2 variants were identified in 46,XY DSD patients. Luciferase assays showed significantly increased transcriptional activation for the p.Asn181del and p.Leu426Arg variants, and protein structure analysis demonstrated impact on protein conformation. ERβ immunostaining confirmed expression in the developing human male embryo intestine and eyes.","method":"Whole-exome sequencing, luciferase transactivation assay, protein structure analysis, immunostaining of human embryo","journal":"Genetics in medicine","confidence":"Medium","confidence_rationale":"Tier 2 — functional variant characterization with reporter assay and structural analysis; novel disease gene identification","pmids":["29261182"],"is_preprint":false},{"year":2019,"finding":"miR-186 and miR-135a directly repress ESR2 expression in granulosa cells, verified by luciferase assays and immunoblotting. Reduced ESR2 further inhibits CDKN1A (p21) expression, promoting granulosa cell proliferation and suppressing apoptosis. Estradiol treatment directly increases miR-186 and miR-135a levels in granulosa cells, creating a feedback loop relevant to PCOS pathophysiology.","method":"Luciferase 3'UTR reporter assay, immunoblotting, miRNA overexpression/inhibition, primary granulosa cell culture","journal":"Molecular and cellular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 — direct target validation by luciferase assay plus functional downstream (CDKN1A) assessment; single lab","pmids":["31173821"],"is_preprint":false},{"year":2020,"finding":"ESR2 (ERβ) acts as a gatekeeper to maintain the primordial follicle reserve. Esr2-null rats show increased primordial follicle activation, premature ovarian senescence, and reduced serum AMH/estradiol. ESR2-selective antagonist PHTPP increases follicle activation in wild-type rats; DPN (selective agonist) decreases it. ESR1 deletion does not increase follicle activation, confirming ESR2-specific regulation. Esr2 DBD mutants also show increased activation, indicating requirement for canonical transcriptional function. Loss of ESR2 augments AKT, ERK, and mTOR pathway activation in both granulosa cells and oocytes.","method":"Esr2-null and DBD-mutant rat models, selective agonist/antagonist pharmacology, follicle counting histology, serum hormone ELISA, Western blot for AKT/ERK/mTOR signaling","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 2 — two genetic models plus pharmacological validation with multiple pathway readouts; pathway placement via signaling analysis","pmids":["32141511"],"is_preprint":false},{"year":2020,"finding":"Complete deletion of all Esr2 exons in mice (Esr2ΔE1-10 via CRISPR/Cas9) establishes that female ERβ-null mice are subfertile at young age and become infertile by ~6 months, with smaller ovaries, very few corpora lutea (indicating ovulation failure), and reduced diestrus estradiol levels. Male Esr2ΔE1-10 mice are fertile. This confirms ERβ's essential role in female reproduction likely through regulation of serum estradiol levels.","method":"CRISPR/Cas9 all-exon deletion, fertility assessment (litter number/size), ovarian histology/corpora lutea counting, serum estradiol measurement","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 2 — complete gene deletion with rigorous phenotypic characterization; cleaner model than prior partial-exon knockouts","pmids":["32703416"],"is_preprint":false},{"year":2019,"finding":"ERβ (ER-β) regulates FATP1/SLC27A1 expression in breast cancer cells. Experiments with estradiol and PHTPP (ERβ antagonist) demonstrated that ERβ regulates FATP1 mRNA expression, fatty acid uptake, and cell viability in four breast cancer cell lines. Inhibition of FATP1 with arylpiperazine 5k interfered with fatty acid uptake and cell viability.","method":"ERβ antagonist (PHTPP) pharmacology, RT-PCR, fatty acid uptake assay, cell viability assay, FATP1 inhibitor","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 3 — pharmacological approach (no genetic KO/KD of ESR2) with multiple cell lines; single lab","pmids":["31575907"],"is_preprint":false},{"year":2021,"finding":"ESR2-mediated estrogen signaling impairs glycemic homeostasis, antagonizing the beneficial effects of ESR1. In Esr2 transgenic mice, GLUT4 (SLC2A4) expression and translocation are reduced. ESR2 acts as a negative regulator of Slc2a4 transcription by genomic mechanisms involving cooperation with other transcription factors, and estradiol-induced ESR2 activation is associated with detrimental effects on glucose metabolism.","method":"Transgenic mouse models (Esr1/Esr2 knockout/overexpression), GLUT4 expression/translocation assays, Slc2a4 promoter analysis, glucose homeostasis measurements","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 — transgenic mouse models with mechanistic gene regulation analysis; review integrating multiple studies","pmids":["33430527"],"is_preprint":false},{"year":2024,"finding":"ESR2 acts as a negative transcription factor that downregulates miR-10a transcription in the prefrontal cortex; miR-10a-5p in turn suppresses BDNF expression. This ESR2→miR-10a-5p⊣BDNF axis contributes to postpartum depression by affecting synaptic plasticity (alterations in SYP, SYN, PSD95, and glutamate receptor expression). Bioinformatics prediction, in vivo animal behavioral studies, cell transfection, and primary neuron culture confirmed the molecular triad. Stereotactic/intranasal antagomir or BDNF administration rescued depressive-like behavior.","method":"Bioinformatics, in vivo behavioral assays, cell transfection, luciferase reporter assay, primary neuron culture, stereotactic/intranasal drug delivery","journal":"Research (Washington, D.C.)","confidence":"Medium","confidence_rationale":"Tier 2 — multiple in vivo and in vitro methods establishing ESR2-miRNA-BDNF pathway; single lab","pmids":["39588356"],"is_preprint":false},{"year":2024,"finding":"LXA4 activates ESR2 in fibroblast-like synoviocytes (FLSs) to inhibit ferroptosis via upregulation of LPAR3, which in turn activates the Nrf2/GPX4/SOD1 axis. LPAR3 overexpression upregulated GPX4, Nrf2, SOD1 and downregulated MMP13/MMP3; LPAR3 knockdown reversed these effects. ESR2-selective antagonist PHTPP partially reversed the improvement in synovial and cartilage pathology induced by exercise in KOA rats, confirming ESR2 involvement in this protective pathway.","method":"Cell co-culture, LPAR3 overexpression/knockdown, Western blot, in vivo KOA rat model with PHTPP antagonist, dataset analysis (GSE29746)","journal":"Redox biology","confidence":"Medium","confidence_rationale":"Tier 2 — loss and gain of function for downstream target (LPAR3) plus in vivo ESR2 antagonism; single lab","pmids":["38754271"],"is_preprint":false},{"year":2021,"finding":"In chicken ovarian theca cells, ESR2 (along with ESR1 and NR5A2) forms a functional transcriptional network regulating CYP19A1 (aromatase) expression. Overexpression of ESR1, ESR2, and NR5A2 in DF-1 cells upregulates CYP19A1 protein and the three factors mutually restrict each other. ESR2 participates in cross-talk regulating theca cell CYP19A1 expression.","method":"Immunofluorescence, Western blot, theca cell culture model, luciferase promoter assay, overexpression in DF-1 cells","journal":"General and comparative endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple methods in avian ortholog context; ortholog finding relevant to mammalian ESR2 function in steroidogenesis","pmids":["34710471"],"is_preprint":false}],"current_model":"ESR2 (estrogen receptor beta, ERβ) is a ligand-activated nuclear receptor that forms homodimers and heterodimers with ERα (and with inactive ERβ isoforms), binds estrogen response elements to regulate transcription, and broadly functions as a dominant negative modulator of ERα activity—repressing cyclin D1, c-myc, and cell cycle progression while inducing p21/p27 to cause G2 arrest—while additionally localizing to mitochondria, suppressing NF-κB-mediated inflammation via non-genomic mechanisms, activating Src/ERK signaling through steroid receptor/Src complexes, regulating primordial follicle activation and ovulation through canonical transcriptional activity in granulosa cells, and participating in neuronal migration, cardiovascular protection, spermatogenesis, and glycemic homeostasis."},"narrative":{"teleology":[{"year":1996,"claim":"The discovery of a second estrogen receptor (ERβ) established that estrogen signaling operates through two independent receptors with conserved DNA-binding but divergent ligand-binding domains, raising the question of whether ERβ has distinct or redundant functions relative to ERα.","evidence":"Degenerate PCR cloning from rat prostate, ligand-binding assay, ERE-reporter transactivation in transfected cells","pmids":["8769313"],"confidence":"High","gaps":["Tissue-specific functions of ERβ versus ERα not yet defined","Endogenous target genes unknown","In vivo role not established"]},{"year":1998,"claim":"Identification of multiple ERβ splice isoforms and demonstration of ERα–ERβ heterodimerization revealed that ERβ could modulate ERα activity through combinatorial dimer formation, with the dominant-negative isoform ERβcx providing a mechanism for ERα inhibition independent of ligand binding.","evidence":"cDNA screening, EMSA for homodimer/heterodimer DNA binding, GST pull-down and co-immunoprecipitation for ERα–ERβ interaction, ligand-binding assays for ERβcx","pmids":["9636657","9473491","9671811"],"confidence":"High","gaps":["In vivo stoichiometry of ERα/ERβ dimers unknown","Physiological relevance of ERβcx in tissues not established","Crystal structure of ERα–ERβ heterodimer unavailable"]},{"year":1999,"claim":"Domain-mapping experiments resolved how ERβ acts as a transdominant inhibitor of ERα: its N-terminal repressor domain and weak AF-1, combined with heterodimerization, reduce estradiol sensitivity and abolish tamoxifen's partial agonist activity through ERα.","evidence":"Domain deletion/chimeric receptor analysis, co-immunoprecipitation, chromatin binding assay, reporter assays in transfected cells","pmids":["10579320"],"confidence":"High","gaps":["Structural basis of the N-terminal repression function unresolved","Chromatin-level mechanism of ligand-independent promoter occupancy not defined"]},{"year":2000,"claim":"In vivo loss-of-function in BERKO mice demonstrated that ERβ restrains ERα-driven uterine proliferation and gene induction (PR, VEGF, IGF-1), while parallel biochemical studies showed ERβ engages non-ERE pathways through direct Sp1 interaction and participates in non-genomic Src/Raf/ERK signaling.","evidence":"ERβ-knockout mouse uterine phenotyping, co-immunoprecipitation of ER–Sp1 complexes, GST pull-down of Src SH2/SH3 domains with ER, microinjection of dominant-negative Src blocking S-phase entry","pmids":["10823946","10681512","11032808"],"confidence":"High","gaps":["Relative contribution of genomic versus non-genomic ERβ signaling in specific tissues unclear","Src interaction site on ERβ not mapped at residue level"]},{"year":2003,"claim":"ERβ was shown to be required for embryonic cortical neuronal migration and survival, extending its role beyond reproductive tissues and establishing a developmental neurobiology function.","evidence":"ERβ-knockout mice with BrdU birth-dating, TUNEL apoptosis assay, immunofluorescence of fragmented radial glia","pmids":["12515851"],"confidence":"High","gaps":["Direct ERβ transcriptional targets in developing brain not identified","Whether mitochondrial ERβ contributes to neuronal survival not tested"]},{"year":2004,"claim":"The antiproliferative mechanism of ERβ was molecularly defined: ERβ represses cyclin D1, c-myc, and cyclin A while inducing p21 and p27, causing G2 arrest and inhibiting xenograft tumor growth, and was simultaneously found to reside predominantly in mitochondria in neurons and cardiomyocytes.","evidence":"Adenoviral ERβ expression in MCF-7 cells with flow cytometry and xenograft assays; subcellular fractionation, confocal colocalization with mitochondrial markers, and mass spectrometry of purified heart mitochondria","pmids":["14729654","14745018","15024130"],"confidence":"High","gaps":["Mitochondrial ERβ target genes/functions not identified","Whether mitochondrial localization is cell-type-restricted remains unclear","Mechanism of mitochondrial import unknown"]},{"year":2006,"claim":"Structural and functional analysis of ERβ isoforms established that a single functional helix 12 within a dimer is sufficient for transactivation, with ERβ1 serving as the obligatory active partner that is enhanced by heterodimerization with ligand-incompetent isoforms under estrogen stimulation.","evidence":"Molecular modeling, co-immunoprecipitation for isoform-specific dimerization, luciferase reporter assays, ligand-binding assays","pmids":["16938840"],"confidence":"High","gaps":["In vivo isoform ratios in specific tissues not quantified","No crystal structures of ERβ isoform heterodimers available"]},{"year":2009,"claim":"ERβ was shown to suppress NF-κB-mediated inflammation by blocking p65 nuclear translocation in macrophages, establishing a non-genomic anti-inflammatory mechanism distinct from its ERE-dependent transcriptional activity.","evidence":"Selective ERβ agonist ERB-041 in peritoneal macrophages, nuclear fractionation for NF-κB p65, ERK inhibitor controls","pmids":["19447495"],"confidence":"Medium","gaps":["Direct molecular interaction between ERβ and NF-κB pathway components not demonstrated","Not confirmed in genetic ERβ-knockout macrophages"]},{"year":2018,"claim":"Genetic models (null and DBD-mutant rats) established that ESR2's canonical DNA-binding function in granulosa cells is required for follicle maturation, ovulation, and direct transcriptional regulation of Kiss1 through ERE binding and cooperation with ERK2-phosphorylated AP-1 factors.","evidence":"Esr2-null and Esr2-DBD mutant rat models, RNA-seq of granulosa cells, ChIP at Kiss1 regulatory regions, ERE mutagenesis/reporter assay, ERK2-ESR2 phosphorylation assay","pmids":["29580824","30277501"],"confidence":"High","gaps":["Full ERβ cistrome in granulosa cells not mapped","Whether Kiss1 regulation by ERβ operates similarly in human granulosa cells not tested"]},{"year":2020,"claim":"ESR2 was identified as the specific gatekeeper of the primordial follicle reserve, restraining AKT/mTOR-driven follicle activation through its transcriptional activity; complete gene deletion confirmed female subfertility progressing to infertility with age.","evidence":"Esr2-null and DBD-mutant rats with selective agonist/antagonist pharmacology, follicle counting, AKT/ERK/mTOR signaling Western blots; CRISPR/Cas9 all-exon deletion mice with fertility and histological assessment","pmids":["32141511","32703416"],"confidence":"High","gaps":["Direct transcriptional targets mediating AKT/mTOR suppression not identified","Whether ESR2 acts cell-autonomously in oocytes versus granulosa cells not fully resolved"]},{"year":2017,"claim":"ESR2 variants (p.Asn181del, p.Leu426Arg) with gain-of-function transcriptional activity were identified in 46,XY DSD patients, implicating ESR2 in human sex development.","evidence":"Whole-exome sequencing of DSD patients, luciferase transactivation assays, protein structure analysis","pmids":["29261182"],"confidence":"Medium","gaps":["Small patient cohort without replication","Mechanism by which gain-of-function ESR2 disrupts male sex development not defined","No rescue or animal model recapitulating these specific variants"]},{"year":null,"claim":"Key unresolved questions include the identity of direct ERβ transcriptional targets in mitochondria, the structural basis of ERα–ERβ heterodimer selectivity at specific promoters, the relative contributions of genomic versus non-genomic ERβ signaling in cardiovascular and neuroprotection, and whether the ESR2–AKT/mTOR axis in follicle maintenance operates through direct target gene regulation.","evidence":"","pmids":[],"confidence":"Low","gaps":["Mitochondrial ERβ targets/import mechanism unknown","No ERα–ERβ heterodimer crystal structure","Cell-autonomous versus paracrine ERβ action in ovarian follicle biology not dissected"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,2,4,5,25]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,5,10,11,13,14,24,25,28,32]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[4,5,7,16]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,5,10,21]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[15]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,5,10,11,13,24,25]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[9,20,28,33]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[13,14]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[12,24,28,29]},{"term_id":"R-HSA-1474165","term_label":"Reproduction","supporting_discovery_ids":[24,28,29]}],"complexes":["ERα/ERβ heterodimer","ERβ homodimer","ER/Src/AR signaling complex"],"partners":["ESR1","SRC","SP1","AHR","ARNT","EP300","NUPR1","AR"],"other_free_text":[]},"mechanistic_narrative":"ESR2 (estrogen receptor beta) is a ligand-activated nuclear receptor that binds 17β-estradiol via a conserved ligand-binding domain and regulates transcription through estrogen response elements (EREs), functioning broadly as an antiproliferative modulator of estrogen signaling that opposes ERα-driven cell cycle progression [PMID:8769313, PMID:10579320, PMID:14729654]. ESR2 heterodimerizes with ERα and with its own splice isoforms—some of which (e.g., ERβcx) lack ligand binding and act as dominant-negative inhibitors of ERα—to repress cyclin D1 and c-myc while inducing p21 and p27, causing G2 arrest and suppressing tumor growth in breast cancer xenografts [PMID:9671811, PMID:11986316, PMID:14729654, PMID:14745018]. Beyond its antiproliferative genomic activity, ESR2 localizes to mitochondria in neurons and cardiomyocytes, activates non-genomic Src/ERK signaling through steroid receptor complexes, suppresses NF-κB nuclear translocation to inhibit inflammation, and protects against cardiac hypertrophy via inhibition of Ca²⁺-calcineurin signaling [PMID:15024130, PMID:11032808, PMID:19447495, PMID:28863192]. ESR2 is essential for female fertility—maintaining the primordial follicle reserve by restraining AKT/mTOR activation and regulating Kiss1 and CYP19A1 in granulosa cells—and is required for embryonic cortical neuronal migration and late brain development [PMID:32141511, PMID:30277501, PMID:12515851, PMID:32703416]."},"prefetch_data":{"uniprot":{"accession":"Q92731","full_name":"Estrogen receptor beta","aliases":["Nuclear receptor subfamily 3 group A member 2"],"length_aa":530,"mass_kda":59.2,"function":"Nuclear hormone receptor. Binds estrogens with an affinity similar to that of ESR1/ER-alpha, and activates expression of reporter genes containing estrogen response elements (ERE) in an estrogen-dependent manner (PubMed:20074560) Lacks ligand binding ability and has no or only very low ERE binding activity resulting in the loss of ligand-dependent transactivation ability","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q92731/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ESR2","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ESR2","total_profiled":1310},"omim":[{"mim_id":"618819","title":"PBX HOMEOBOX-INTERACTING PROTEIN 1; PBXIP1","url":"https://www.omim.org/entry/618819"},{"mim_id":"618187","title":"OVARIAN DYSGENESIS 8; ODG8","url":"https://www.omim.org/entry/618187"},{"mim_id":"617856","title":"THYMOCYTE SELECTION-ASSOCIATED PROTEIN FAMILY, MEMBER 2; THEMIS2","url":"https://www.omim.org/entry/617856"},{"mim_id":"617639","title":"DEAFNESS, AUTOSOMAL RECESSIVE 107; DFNB107","url":"https://www.omim.org/entry/617639"},{"mim_id":"616825","title":"NUCLEAR RECEPTOR COACTIVATOR 5; NCOA5","url":"https://www.omim.org/entry/616825"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Vesicles","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"adrenal gland","ntpm":6.5},{"tissue":"ovary","ntpm":6.2},{"tissue":"testis","ntpm":5.6}],"url":"https://www.proteinatlas.org/search/ESR2"},"hgnc":{"alias_symbol":["NR3A2","Erb","ER-beta"],"prev_symbol":[]},"alphafold":{"accession":"Q92731","domains":[{"cath_id":"3.30.50.10","chopping":"157-211","consensus_level":"high","plddt":93.872,"start":157,"end":211},{"cath_id":"1.10.565.10","chopping":"264-410_418-503","consensus_level":"high","plddt":91.5539,"start":264,"end":503}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q92731","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q92731-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q92731-F1-predicted_aligned_error_v6.png","plddt_mean":69.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ESR2","jax_strain_url":"https://www.jax.org/strain/search?query=ESR2"},"sequence":{"accession":"Q92731","fasta_url":"https://rest.uniprot.org/uniprotkb/Q92731.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q92731/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q92731"}},"corpus_meta":[{"pmid":"2879243","id":"PMC_2879243","title":"The c-erb-A gene encodes a thyroid hormone receptor.","date":"1986","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/2879243","citation_count":1503,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2879242","id":"PMC_2879242","title":"The c-erb-A protein is a high-affinity receptor for thyroid hormone.","date":"1986","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/2879242","citation_count":1316,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22460952","id":"PMC_22460952","title":"Regulation of circadian behaviour and metabolism by REV-ERB-α and REV-ERB-β.","date":"2012","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/22460952","citation_count":871,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22460951","id":"PMC_22460951","title":"Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists.","date":"2012","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/22460951","citation_count":672,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16267379","id":"PMC_16267379","title":"Differential control of Bmal1 circadian transcription by REV-ERB and ROR nuclear receptors.","date":"2005","source":"Journal of biological rhythms","url":"https://pubmed.ncbi.nlm.nih.gov/16267379","citation_count":569,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24577401","id":"PMC_24577401","title":"REV-ERB and ROR nuclear receptors as drug targets.","date":"2014","source":"Nature reviews. Drug discovery","url":"https://pubmed.ncbi.nlm.nih.gov/24577401","citation_count":467,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10823946","id":"PMC_10823946","title":"Estrogen receptor (ER) beta, a modulator of ERalpha in the uterus.","date":"2000","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10823946","citation_count":395,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11517191","id":"PMC_11517191","title":"ER beta inhibits proliferation and invasion of breast cancer cells.","date":"2001","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/11517191","citation_count":339,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3841189","id":"PMC_3841189","title":"Domain structure of human glucocorticoid receptor and its relationship to the v-erb-A oncogene product.","date":"1985","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/3841189","citation_count":318,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12515851","id":"PMC_12515851","title":"Estrogen receptor (ER)beta knockout mice reveal a role for ERbeta in migration of cortical neurons in the developing brain.","date":"2003","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12515851","citation_count":187,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19696364","id":"PMC_19696364","title":"Rev-erb-alpha: an integrator of circadian rhythms and metabolism.","date":"2009","source":"Journal of applied physiology (Bethesda, Md. : 1985)","url":"https://pubmed.ncbi.nlm.nih.gov/19696364","citation_count":141,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31127047","id":"PMC_31127047","title":"SR9009 has REV-ERB-independent effects on cell proliferation and metabolism.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/31127047","citation_count":136,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22161825","id":"PMC_22161825","title":"The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology.","date":"2011","source":"The International journal of developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/22161825","citation_count":136,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21479263","id":"PMC_21479263","title":"Direct regulation of CLOCK expression by REV-ERB.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21479263","citation_count":129,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16024756","id":"PMC_16024756","title":"Estrogen and the brain: beyond ER-alpha, ER-beta, and 17beta-estradiol.","date":"2005","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/16024756","citation_count":128,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20018698","id":"PMC_20018698","title":"PGC-1alpha negatively regulates hepatic FGF21 expression by modulating the heme/Rev-Erb(alpha) axis.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/20018698","citation_count":120,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20427485","id":"PMC_20427485","title":"Regulation of adipogenesis by natural and synthetic REV-ERB ligands.","date":"2010","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/20427485","citation_count":111,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15863464","id":"PMC_15863464","title":"Dilated cardiomyopathy in Erb-b4-deficient ventricular muscle.","date":"2005","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/15863464","citation_count":106,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20534529","id":"PMC_20534529","title":"E3 ligases Arf-bp1 and Pam mediate lithium-stimulated degradation of the circadian heme receptor Rev-erb alpha.","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/20534529","citation_count":86,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2892305","id":"PMC_2892305","title":"Light and electron microscopical demonstration of c- erB-2 gene product-like immunoreactivity in human malignant tumors.","date":"1987","source":"Virchows Archiv. B, Cell pathology including molecular pathology","url":"https://pubmed.ncbi.nlm.nih.gov/2892305","citation_count":83,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6328316","id":"PMC_6328316","title":"Identification of a form of the avian erythroblastosis virus erb-B gene product at the cell surface.","date":"1984","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/6328316","citation_count":83,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15477868","id":"PMC_15477868","title":"Inverse relationship between ER-beta and SRC-1 predicts outcome in endocrine-resistant breast cancer.","date":"2004","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15477868","citation_count":81,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33430527","id":"PMC_33430527","title":"Estrogen and Glycemic Homeostasis: The Fundamental Role of Nuclear Estrogen Receptors ESR1/ESR2 in Glucose Transporter GLUT4 Regulation.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/33430527","citation_count":81,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9829551","id":"PMC_9829551","title":"Oestrogen receptor beta (ER beta).","date":"1998","source":"Reviews of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/9829551","citation_count":81,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29232411","id":"PMC_29232411","title":"Rev-erb agonist improves adverse cardiac remodeling and survival in myocardial infarction through an anti-inflammatory mechanism.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/29232411","citation_count":78,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35034472","id":"PMC_35034472","title":"Myocardial Rev-erb-Mediated Diurnal Metabolic Rhythm and Obesity Paradox.","date":"2022","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/35034472","citation_count":75,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15582272","id":"PMC_15582272","title":"Estrogen and the brain: beyond ER-alpha and ER-beta.","date":"2004","source":"Experimental gerontology","url":"https://pubmed.ncbi.nlm.nih.gov/15582272","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25800870","id":"PMC_25800870","title":"Suppression of atherosclerosis by synthetic REV-ERB agonist.","date":"2015","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/25800870","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29580824","id":"PMC_29580824","title":"ESR2 regulates granulosa cell genes essential for follicle maturation and ovulation.","date":"2018","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/29580824","citation_count":71,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18056768","id":"PMC_18056768","title":"Ligand-dependent activation of ER{beta} lowers blood pressure and attenuates cardiac hypertrophy in ovariectomized spontaneously hypertensive rats.","date":"2007","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/18056768","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33762728","id":"PMC_33762728","title":"REV-ERB in GABAergic neurons controls diurnal hepatic insulin sensitivity.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/33762728","citation_count":66,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18996135","id":"PMC_18996135","title":"Effect of ER-beta gene disruption on estrogenic regulation of anxiety in female mice.","date":"2008","source":"Physiology & behavior","url":"https://pubmed.ncbi.nlm.nih.gov/18996135","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26611104","id":"PMC_26611104","title":"Coactivator-Dependent Oscillation of Chromatin Accessibility Dictates Circadian Gene Amplitude via REV-ERB Loading.","date":"2015","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/26611104","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21408158","id":"PMC_21408158","title":"Nuclear receptor Rev-erb alpha (Nr1d1) functions in concert with Nr2e3 to regulate transcriptional networks in the retina.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21408158","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11803451","id":"PMC_11803451","title":"Variation in the ESR1 and ESR2 genes and genetic susceptibility to anorexia nervosa.","date":"2002","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/11803451","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27004961","id":"PMC_27004961","title":"Differential roles of estrogen receptors, ESR1 and ESR2, in adult rat spermatogenesis.","date":"2016","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/27004961","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24352099","id":"PMC_24352099","title":"Sex-specific Esr2 mRNA expression in the rat hypothalamus and amygdala is altered by neonatal bisphenol A exposure.","date":"2014","source":"Reproduction (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/24352099","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21600396","id":"PMC_21600396","title":"Arabidopsis ENHANCER OF SHOOT REGENERATION (ESR)1 and ESR2 regulate in vitro shoot regeneration and their expressions are differentially regulated.","date":"2011","source":"Plant science : an international journal of experimental plant biology","url":"https://pubmed.ncbi.nlm.nih.gov/21600396","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17525739","id":"PMC_17525739","title":"AP-2 regulates the transcription of estrogen receptor (ER)-beta by acting through a methylation hotspot of the 0N promoter in prostate cancer cells.","date":"2007","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/17525739","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24735329","id":"PMC_24735329","title":"ESR1 and ESR2 differentially regulate daily and circadian activity rhythms in female mice.","date":"2014","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/24735329","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18375409","id":"PMC_18375409","title":"Genetic polymorphisms of ESR1 and ESR2 that may influence estrogen activity and the risk of hypospadias.","date":"2008","source":"Human reproduction (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/18375409","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20586553","id":"PMC_20586553","title":"Polymorphisms in ESR1, ESR2 and HSD17B1 genes are associated with fertility status in endometriosis.","date":"2010","source":"Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/20586553","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31825658","id":"PMC_31825658","title":"Chemotherapeutic Effect of SR9009, a REV-ERB Agonist, on the Human Glioblastoma T98G Cells.","date":"2019","source":"ASN neuro","url":"https://pubmed.ncbi.nlm.nih.gov/31825658","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17490623","id":"PMC_17490623","title":"Age-related changes in the expression of ER-beta mRNA in the female rat brain.","date":"2007","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/17490623","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2904292","id":"PMC_2904292","title":"Hypomethylation of ornithine decarboxylase gene and erb-A1 oncogene in human chronic lymphatic leukemia.","date":"1988","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/2904292","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15781258","id":"PMC_15781258","title":"Com-1/P8 in oestrogen regulated growth of breast cancer cells, the ER-beta connection.","date":"2005","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15781258","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9458291","id":"PMC_9458291","title":"c-myc, c-erb-B2, nm23 and p53 expression in human endometriosis.","date":"1998","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/9458291","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32764708","id":"PMC_32764708","title":"Pharmacological activation of the circadian component REV-ERB inhibits HIV-1 replication.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32764708","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22828941","id":"PMC_22828941","title":"Impact of REV-ERB alpha gene polymorphisms on obesity phenotypes in adult and adolescent samples.","date":"2012","source":"International journal of obesity (2005)","url":"https://pubmed.ncbi.nlm.nih.gov/22828941","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29401617","id":"PMC_29401617","title":"REV-ERB agonism suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss partially via FABP4 upregulation.","date":"2018","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/29401617","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18511514","id":"PMC_18511514","title":"Estrogen receptor (ER) beta modulates ERalpha responses to estrogens in the developing rat ventromedial nucleus of the hypothalamus.","date":"2008","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/18511514","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32141511","id":"PMC_32141511","title":"A Gatekeeping Role of ESR2 to Maintain the Primordial Follicle Reserve.","date":"2020","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/32141511","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24173768","id":"PMC_24173768","title":"REV-ERB-ALPHA circadian gene variant associates with obesity in two independent populations: Mediterranean and North American.","date":"2013","source":"Molecular nutrition & food research","url":"https://pubmed.ncbi.nlm.nih.gov/24173768","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39588356","id":"PMC_39588356","title":"Deciphering and Targeting the ESR2-miR-10a-5p-BDNF Axis in the Prefrontal Cortex: Advancing Postpartum Depression Understanding and Therapeutics.","date":"2024","source":"Research (Washington, D.C.)","url":"https://pubmed.ncbi.nlm.nih.gov/39588356","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38754271","id":"PMC_38754271","title":"Lipoxin A4 ameliorates knee osteoarthritis progression in rats by antagonizing ferroptosis through activation of the ESR2/LPAR3/Nrf2 axis in synovial fibroblast-like synoviocytes.","date":"2024","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/38754271","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29215066","id":"PMC_29215066","title":"Pharmacological inhibition of REV-ERB stimulates differentiation, inhibits turnover and reduces fibrosis in dystrophic muscle.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29215066","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25526766","id":"PMC_25526766","title":"ESR1 and ESR2 gene polymorphisms are associated with human reproduction outcomes in Brazilian women.","date":"2014","source":"Journal of ovarian research","url":"https://pubmed.ncbi.nlm.nih.gov/25526766","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18487282","id":"PMC_18487282","title":"Association between ESR2 genetic variants and risk of myocardial infarction.","date":"2008","source":"Clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18487282","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15161628","id":"PMC_15161628","title":"Estrogen receptor-1 (Esr1) and -2 (Esr2) regulate the severity of clinical experimental allergic encephalomyelitis in male mice.","date":"2004","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15161628","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18569528","id":"PMC_18569528","title":"Estrogen receptors alpha (ESR1) and beta (ESR2) are expressed in circulating human lymphocytes.","date":"2008","source":"Journal of receptor and signal transduction research","url":"https://pubmed.ncbi.nlm.nih.gov/18569528","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36414641","id":"PMC_36414641","title":"Structural basis of synthetic agonist activation of the nuclear receptor REV-ERB.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36414641","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28213272","id":"PMC_28213272","title":"Rev-erb regulation of cholesterologenesis.","date":"2017","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28213272","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31173821","id":"PMC_31173821","title":"Altered miR-186 and miR-135a contribute to granulosa cell dysfunction by targeting ESR2: A possible role in polycystic ovary syndrome.","date":"2019","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/31173821","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32738989","id":"PMC_32738989","title":"The transcriptional repressor REV-ERB as a novel target for disease.","date":"2020","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/32738989","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30277501","id":"PMC_30277501","title":"ESR2 Is Essential for Gonadotropin-Induced Kiss1 Expression in Granulosa Cells.","date":"2018","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/30277501","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31575907","id":"PMC_31575907","title":"Unraveling FATP1, regulated by ER-β, as a targeted breast cancer innovative therapy.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31575907","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29261182","id":"PMC_29261182","title":"Biallelic and monoallelic ESR2 variants associated with 46,XY disorders of sex development.","date":"2017","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29261182","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19429453","id":"PMC_19429453","title":"Polymorphisms in the promoter region of ESR2 gene and breast cancer susceptibility.","date":"2009","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/19429453","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19447495","id":"PMC_19447495","title":"ERB-041, a selective ER beta agonist, inhibits iNOS production in LPS-activated peritoneal macrophages of endometriosis via suppression of NF-kappaB activation.","date":"2009","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19447495","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21174621","id":"PMC_21174621","title":"The effect of ESR1 and ESR2 gene polymorphisms on the outcome of rheumatoid arthritis treatment with leflunomide.","date":"2011","source":"Pharmacogenomics","url":"https://pubmed.ncbi.nlm.nih.gov/21174621","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28990415","id":"PMC_28990415","title":"Redox Regulation of Heme Oxygenase-2 and the Transcription Factor, Rev-Erb, Through Heme Regulatory Motifs.","date":"2017","source":"Antioxidants & redox signaling","url":"https://pubmed.ncbi.nlm.nih.gov/28990415","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24647635","id":"PMC_24647635","title":"Association of polymorphisms in estrogen receptors (ESR1 and ESR2) with male infertility: a meta-analysis and systematic review.","date":"2014","source":"Journal of assisted reproduction and genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24647635","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22613952","id":"PMC_22613952","title":"REV-ERB-erating nuclear receptor functions in circadian metabolism and physiology.","date":"2012","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/22613952","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29664547","id":"PMC_29664547","title":"HSD3B2, HSD17B1, HSD17B2, ESR1, ESR2 and AR expression in infertile women with endometriosis.","date":"2018","source":"Ginekologia polska","url":"https://pubmed.ncbi.nlm.nih.gov/29664547","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24859835","id":"PMC_24859835","title":"The influence of ESR1 rs9340799 and ESR2 rs1256049 polymorphisms on prostate cancer risk.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24859835","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18164902","id":"PMC_18164902","title":"Analyses of variants located in estrogen metabolism genes (ESR1, ESR2, COMT and APOE) and schizophrenia.","date":"2007","source":"Schizophrenia research","url":"https://pubmed.ncbi.nlm.nih.gov/18164902","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29535531","id":"PMC_29535531","title":"Genetic association between HER2 and ESR2 polymorphisms and ovarian cancer: a meta-analysis.","date":"2018","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/29535531","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7546049","id":"PMC_7546049","title":"Correlation between ploidy status, Erb-B2 and p53 immunohistochemical expression in primary breast carcinoma.","date":"1995","source":"Analytical and quantitative cytology and histology","url":"https://pubmed.ncbi.nlm.nih.gov/7546049","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15688609","id":"PMC_15688609","title":"Early phase I data on an irreversible pan-erb inhibitor: CI-1033. What did we learn?","date":"2004","source":"Journal of chemotherapy (Florence, Italy)","url":"https://pubmed.ncbi.nlm.nih.gov/15688609","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18312354","id":"PMC_18312354","title":"The potential role of ER beta isoforms in the clinical management of breast cancer.","date":"2008","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/18312354","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33339862","id":"PMC_33339862","title":"Methylation of estrogen receptor 2 (ESR2) in deep paravertebral muscles and its association with idiopathic scoliosis.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33339862","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28863192","id":"PMC_28863192","title":"E2/ER β inhibit ISO-induced cardiac cellular hypertrophy by suppressing Ca2+-calcineurin signaling.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28863192","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12683943","id":"PMC_12683943","title":"A specific and unusual nuclear localization signal in the DNA binding domain of the Rev-erb orphan receptors.","date":"2003","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/12683943","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34207568","id":"PMC_34207568","title":"Altered Expression of ESR1, ESR2, PELP1 and c-SRC Genes Is Associated with Ovarian Cancer Manifestation.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34207568","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14973391","id":"PMC_14973391","title":"The normal and malignant mammary gland: a fresh look with ER beta onboard.","date":"2000","source":"Journal of mammary gland biology and neoplasia","url":"https://pubmed.ncbi.nlm.nih.gov/14973391","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25463985","id":"PMC_25463985","title":"Genetic polymorphisms in ESR1 and ESR2 genes, and risk of hypospadias in a multiethnic study population.","date":"2014","source":"The Journal of urology","url":"https://pubmed.ncbi.nlm.nih.gov/25463985","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30811380","id":"PMC_30811380","title":"Endothelin receptor Aa regulates proliferation and differentiation of Erb-dependent pigment progenitors in zebrafish.","date":"2019","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30811380","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30395700","id":"PMC_30395700","title":"A further insight into the metabolic profile of the nuclear receptor Rev-erb agonist, SR9009.","date":"2018","source":"Drug testing and analysis","url":"https://pubmed.ncbi.nlm.nih.gov/30395700","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24881814","id":"PMC_24881814","title":"Polymorphisms in the promoter region of ESR2 gene and susceptibility to ovarian cancer.","date":"2014","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/24881814","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32703416","id":"PMC_32703416","title":"Generation of an all-exon Esr2 deleted mouse line: Effects on fertility.","date":"2020","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/32703416","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26590813","id":"PMC_26590813","title":"ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer.","date":"2015","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/26590813","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34710471","id":"PMC_34710471","title":"Transcriptional regulation of CYP19A1 expression in chickens: ESR1, ESR2 and NR5A2 form a functional network.","date":"2021","source":"General and comparative endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/34710471","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35911512","id":"PMC_35911512","title":"SR9009 improves heart function after pressure overload independent of cardiac REV-ERB.","date":"2022","source":"Frontiers in cardiovascular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35911512","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27737359","id":"PMC_27737359","title":"Analysis of polymorphisms in Interleukin 10, NOS2A, and ESR2 genes in chronic and aggressive periodontitis.","date":"2016","source":"Brazilian oral research","url":"https://pubmed.ncbi.nlm.nih.gov/27737359","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26147849","id":"PMC_26147849","title":"Changes in Estrogen Receptor ERβ (ESR2) Expression without Changes in the Estradiol Levels in the Prostate of Aging Rats.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26147849","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31698960","id":"PMC_31698960","title":"Environmental polycyclic aromatic hydrocarbons mixture, in human blood levels, decreased oestradiol secretion by granulosa cells via ESR1 and GPER1 but not ESR2 receptor.","date":"2019","source":"Human & experimental toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/31698960","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9702737","id":"PMC_9702737","title":"Estrogen action in the estrogen receptor alpha-knockout mouse: is this due to ER-beta?","date":"1998","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/9702737","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6092923","id":"PMC_6092923","title":"Cellular oncogenes (c-erb-A and c-erb-B) located on different chicken chromosomes can be transduced into the same retroviral genome.","date":"1984","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/6092923","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38281964","id":"PMC_38281964","title":"Exploring the association of ESR1 and ESR2 gene SNPs with polycystic ovary syndrome in human females: a comprehensive association study.","date":"2024","source":"Journal of ovarian research","url":"https://pubmed.ncbi.nlm.nih.gov/38281964","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31888550","id":"PMC_31888550","title":"Association between ESR1, ESR2, HER2, UGT1A4, and UGT2B7 polymorphisms and breast Cancer in Jordan: a case-control study.","date":"2019","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31888550","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8769313","id":"PMC_8769313","title":"ER beta: identification and characterization of a novel human estrogen receptor.","date":"1996","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/8769313","citation_count":1838,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9267036","id":"PMC_9267036","title":"Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300.","date":"1997","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/9267036","citation_count":1255,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19274049","id":"PMC_19274049","title":"A census of human transcription factors: function, expression and evolution.","date":"2009","source":"Nature reviews. Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19274049","citation_count":1191,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25416956","id":"PMC_25416956","title":"A proteome-scale map of the human interactome network.","date":"2014","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/25416956","citation_count":977,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9398750","id":"PMC_9398750","title":"Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern.","date":"1997","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/9398750","citation_count":961,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10579320","id":"PMC_10579320","title":"The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens.","date":"1999","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/10579320","citation_count":878,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12774124","id":"PMC_12774124","title":"Modulation of oestrogen receptor signalling by association with the activated dioxin receptor.","date":"2003","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/12774124","citation_count":610,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8221895","id":"PMC_8221895","title":"The crystal structure of the estrogen receptor DNA-binding domain bound to DNA: how receptors discriminate between their response elements.","date":"1993","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/8221895","citation_count":586,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8197458","id":"PMC_8197458","title":"Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription.","date":"1994","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/8197458","citation_count":569,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11032808","id":"PMC_11032808","title":"Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation.","date":"2000","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/11032808","citation_count":560,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14729654","id":"PMC_14729654","title":"Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest.","date":"2004","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/14729654","citation_count":503,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22544366","id":"PMC_22544366","title":"Meta-analysis identifies six new susceptibility loci for atrial fibrillation.","date":"2012","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22544366","citation_count":490,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25910212","id":"PMC_25910212","title":"Widespread macromolecular interaction perturbations in human genetic disorders.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/25910212","citation_count":454,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14745018","id":"PMC_14745018","title":"Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/14745018","citation_count":449,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9636657","id":"PMC_9636657","title":"Cloning and characterization of human estrogen receptor beta isoforms.","date":"1998","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9636657","citation_count":447,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18216219","id":"PMC_18216219","title":"Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.","date":"2008","source":"Endocrine reviews","url":"https://pubmed.ncbi.nlm.nih.gov/18216219","citation_count":436,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16645038","id":"PMC_16645038","title":"Nature of functional estrogen receptors at the plasma membrane.","date":"2006","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/16645038","citation_count":429,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9473491","id":"PMC_9473491","title":"The complete primary structure of human estrogen receptor beta (hER beta) and its heterodimerization with ER alpha in vivo and in vitro.","date":"1998","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9473491","citation_count":417,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15024130","id":"PMC_15024130","title":"Mitochondrial localization of estrogen receptor beta.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15024130","citation_count":410,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10749889","id":"PMC_10749889","title":"Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10749889","citation_count":391,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11181953","id":"PMC_11181953","title":"Role of estrogen receptor beta in estrogen action.","date":"2001","source":"Annual review of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11181953","citation_count":382,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9671811","id":"PMC_9671811","title":"Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor ofestrogen action in human.","date":"1998","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/9671811","citation_count":373,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11986316","id":"PMC_11986316","title":"Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11986316","citation_count":372,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10681512","id":"PMC_10681512","title":"Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10681512","citation_count":331,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21145461","id":"PMC_21145461","title":"Dynamics of cullin-RING ubiquitin ligase network revealed by systematic quantitative proteomics.","date":"2010","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/21145461","citation_count":318,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16938840","id":"PMC_16938840","title":"Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16938840","citation_count":313,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48757,"output_tokens":5219,"usd":0.112278},"stage2":{"model":"claude-opus-4-6","input_tokens":8926,"output_tokens":6054,"usd":0.29397},"total_usd":0.804129,"stage1_batch_id":"msgbatch_0118RScg3WGaGkaZRtWZbtce","stage2_batch_id":"msgbatch_01Cpfzvtbj42aqp5oYZ5Te2s","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":60739,"output_tokens":9616,"usd":0.163228},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":14142,"output_tokens":3429,"usd":0.234653}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"ERβ (ESR2) acts as a modulator of ERα in the uterus: in ERβ knockout mice, the immature uterus shows elevated progesterone receptor and Ki-67 levels and exaggerated responsiveness to estradiol, demonstrating an antiproliferative and ERα-modulatory role for ERβ\",\n      \"method\": \"ERβ knockout (BERKO) mouse model with histology, immunohistochemistry, and gene expression analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with multiple defined cellular/molecular phenotypes, replicated across multiple readouts\",\n      \"pmids\": [\"10823946\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"ERβ (ESR2) localizes to the nucleus and can transactivate estrogen-responsive reporter constructs in the presence of E2; it inhibits MDA-MB-231 breast cancer cell proliferation in a ligand-independent manner and decreases cell motility and invasion; unlike ERα, ERβ cannot regulate c-myc expression\",\n      \"method\": \"Adenoviral re-expression of ERβ in ER-negative MDA-MB-231 cells; RT-PCR, Western blot, immunocytochemistry, reporter assays, proliferation and invasion assays\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reconstitution via adenoviral vector with multiple orthogonal functional readouts in a defined cellular system\",\n      \"pmids\": [\"11517191\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ESR2 is required for cortical neuronal migration and survival during late embryonic brain development; ERβ knockout mice show fewer neurons in the cortex, fragmented radial glia processes, and increased apoptosis in the ventricular zone at E18.5, without differences in neurogenesis\",\n      \"method\": \"ERβ knockout mice; BrdUrd labeling of proliferating cells at E12.5 and E14.5; examination at E18.5 and postnatal day 14; immunohistochemistry for apoptotic markers and radial glia\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with BrdUrd pulse-chase and multiple cellular phenotype readouts establishing a specific developmental role\",\n      \"pmids\": [\"12515851\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Selective ERβ agonist (8β-VE2) lowers elevated blood pressure and attenuates cardiac hypertrophy in ovariectomized spontaneously hypertensive rats via improved NO-dependent vasorelaxation and enhanced phosphorylation of vasodilator-stimulated phosphoprotein, without uterotrophic effects\",\n      \"method\": \"12-week pharmacological treatment with selective ERβ agonist in ovariectomized SHR; echocardiography, aortic ring tension studies, immunoblotting for phospho-VASP\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — selective agonist with functional vascular phenotype readouts, single lab\",\n      \"pmids\": [\"18056768\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"AP-2α and AP-2γ transcription factors directly regulate ESR2 transcription by binding to a methylation hotspot (center 1) in the 0N promoter; forced expression of AP-2α or AP-2γ increased ERβ promoter activity and mRNA levels, while siRNA knockdown reduced them\",\n      \"method\": \"Deletion analysis, chromatin immunoprecipitation (ChIP), forced AP-2 expression, siRNA knockdown, luciferase reporter assays in prostate cancer cells\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — ChIP with gain- and loss-of-function experiments and reporter assays providing mechanistic chain\",\n      \"pmids\": [\"17525739\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ERβ (ESR2) inhibits ERα activity in an anatomically specific manner in the neonatal brain: selective activation of ERβ attenuates ERα-mediated progesterone receptor induction in the ventromedial nucleus but not the medial preoptic nucleus\",\n      \"method\": \"Selective ER agonist administration in neonatal rats; immunohistochemistry for progesterone receptor in specific hypothalamic nuclei\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — selective agonist approach with anatomically specific functional readout, single lab\",\n      \"pmids\": [\"18511514\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Selective ERβ agonist (ERB-041) inhibits LPS-induced iNOS production in peritoneal macrophages from endometriosis patients via suppression of NF-κB nuclear translocation, but not via ERK signaling\",\n      \"method\": \"ERβ agonist treatment of primary peritoneal macrophages; RT-PCR, immunoblot for iNOS, p65, ERK; nuclear fractionation\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — selective agonist with pathway dissection (NF-κB vs ERK), single lab\",\n      \"pmids\": [\"19447495\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ESR2/ERβ, together with E2, suppresses ISO-induced cardiac cellular hypertrophy in H9c2 cardiomyoblasts by inhibiting Ca2+-calcineurin signaling; ERβ overexpression or E2 treatment reduces p-CaMKII, calcineurin, p-GATA4, and NFATc3 levels and blocks NFATc3 nuclear translocation; the mechanism involves ESR2 activating I-1 protein to suppress PP1, promoting phospholamban phosphorylation and Ca2+ reuptake into the SR\",\n      \"method\": \"ERβ overexpression in H9c2 cells; isoproterenol stimulation; calcineurin inhibitor (CsA) and calcium blocker (BAPTA) experiments; immunoblotting for hypertrophic markers, Ca2+ signaling components\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — overexpression with pharmacological pathway dissection and multiple molecular readouts, single lab\",\n      \"pmids\": [\"28863192\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ESR2 regulates genes in granulosa cells essential for follicle maturation and ovulation, including Kiss1; ESR2 null and DNA-binding domain mutant rats both fail to ovulate, indicating that ESR2 transcriptional activity (via its DBD) is required; RNA-seq identified 1,696 differentially expressed genes in granulosa cells involving steroidogenesis, follicle maturation, and ovulation pathways\",\n      \"method\": \"Esr2 null and DBD-mutant rat models; exogenous gonadotropin stimulation; RNA-sequencing of granulosa cells; pathway analysis\",\n      \"journal\": \"Molecular and cellular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — two complementary genetic models (null and DBD mutant) with transcriptomic phenotyping establish transcriptional mechanism\",\n      \"pmids\": [\"29580824\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ESR2 is essential for gonadotropin-induced Kiss1 expression in granulosa cells; ESR2 binds to estrogen response elements (EREs) in the Kiss1 promoter and two enhancers; gonadotropins phosphorylate ESR2 via MAPK ERK2 and upregulate AP-1 factors (FOSL2, JUNB) that synergistically activate the Kiss1 promoter with ESR2\",\n      \"method\": \"ChIP for ESR2 and histone marks at Kiss1 regulatory regions; ERE mutation in luciferase reporter; ESR2 overexpression; pharmacological ERK inhibition; Co-immunoprecipitation of ESR2 phosphorylation\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — ChIP, mutagenesis of ERE, reporter assays, and kinase pathway experiments establish direct transcriptional mechanism\",\n      \"pmids\": [\"30277501\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ESR2 variants identified in 46,XY DSD: a homozygous deletion in the DNA-binding domain (p.Asn181del) leads to significantly increased transcriptional activation; a missense variant in the ligand-binding domain (p.Leu426Arg) impacts protein conformation; ESR2/ERβ protein is expressed in the developing human male gonad\",\n      \"method\": \"Whole-exome sequencing, luciferase transcriptional activation assays, protein structure analysis, immunostaining of human embryonic tissue\",\n      \"journal\": \"Genetics in medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional luciferase assays with structure analysis; single study\",\n      \"pmids\": [\"29261182\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ESR2 acts as a gatekeeper to maintain the primordial follicle reserve by suppressing follicle activation; ESR2 loss leads to increased AKT, ERK, and mTOR pathway activation in the ovary, causing excessive primordial follicle recruitment and premature ovarian senescence; selective ESR2 antagonist (PHTPP) increases follicle activation while agonist (DPN) decreases it; ESR1 loss does not recapitulate this phenotype, indicating ESR2 specificity\",\n      \"method\": \"Esr2-/- rat model; ESR2 selective agonist/antagonist pharmacology; immunohistochemistry and follicle counting; phospho-AKT, ERK, mTOR immunoblotting; comparison with ESR1 null\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO, pharmacological rescue, pathway analysis with receptor-subtype specificity established by ESR1 comparison\",\n      \"pmids\": [\"32141511\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Complete Esr2 gene deletion in mice causes female subfertility with fewer litters and smaller litter size, progressing to infertility by ~6 months; ovaries show few corpora lutea (defective ovulation) and reduced estradiol at diestrus; male Esr2 deletion does not affect fertility\",\n      \"method\": \"CRISPR/Cas9 all-exon Esr2 deletion mouse line; fertility tracking; ovarian histology; serum estradiol measurement\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — complete gene deletion with multiple reproductive phenotype readouts; clarifies prior controversies with total knockout\",\n      \"pmids\": [\"32703416\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ESR2 activation (via selective agonist) reduces sperm counts in adult male rats due to spermiation failure caused by defects in tubulobulbar complex formation (from decreased actin remodeling gene expression) and increased spermatocyte apoptosis via oxidative stress; ESR1 activation causes spermiogenesis arrest through different genes, establishing distinct roles for the two receptors\",\n      \"method\": \"Selective ESR1 and ESR2 agonist administration in adult male rats; histology; gene expression analysis; sperm count measurement\",\n      \"journal\": \"Molecular and cellular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — selective agonist approach with subtype-specific phenotypic dissection, single lab\",\n      \"pmids\": [\"27004961\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Com-1/P8 protein physically interacts with ERβ (ESR2) in breast cancer cells (co-immunoprecipitation); both proteins co-localize in the nucleus; 17β-estradiol stimulation reduces nuclear Com-1, a reduction prevented by proteasome inhibitors, implicating the ubiquitin-proteasome pathway in the ESR2/Com-1 complex\",\n      \"method\": \"Co-immunoprecipitation, immunocytochemistry, proteasome inhibitor treatment (ubiquitin aldehyde, lactacystin) in MDA-MB-231 cells\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single Co-IP with follow-up proteasome experiments, single lab\",\n      \"pmids\": [\"15781258\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ESR1 and ESR2 exert distinct effects on daily and circadian activity rhythms in female mice: ESR1 activation increases total wheel running and consolidates activity to the dark phase, while ESR2 activation modifies the temporal distribution of activity, delays the acrophase of wheel running, and attenuates the circadian phase response to early-night light pulses\",\n      \"method\": \"Ovariectomized female mice treated with selective ESR1 (PPT) or ESR2 (DPN) agonists; wheel-running activity recording in 12h:12h LD or constant darkness; light-pulse phase-response experiments\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — selective agonists with clear receptor-subtype-specific circadian behavioral phenotypes, single lab\",\n      \"pmids\": [\"24735329\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ESR2 acts as a negative transcription factor that down-regulates miR-10a transcription in the prefrontal cortex; miR-10a-5p in turn suppresses BDNF expression; this ESR2-miR-10a-5p-BDNF axis affects synaptic plasticity (SYP, SYN, PSD95, glutamate receptors) and contributes to postpartum depressive-like behavior in mice\",\n      \"method\": \"Animal behavioral studies; bioinformatics; luciferase assays; in vivo and cell transfection; primary neuron culture; stereotactic/intranasal antagomir and BDNF administration\",\n      \"journal\": \"Research (Washington, D.C.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (luciferase, transfection, in vivo rescue) establishing negative transcriptional regulation, single lab\",\n      \"pmids\": [\"39588356\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"miR-186 and miR-135a directly repress ESR2 expression in granulosa cells (validated by luciferase assays and immunoblotting); reduced ESR2 in turn inhibits CDKN1A expression, promoting granulosa cell proliferation and repressing apoptosis; estradiol treatment directly increases miR-186 and miR-135a levels in KGN and primary granulosa cells\",\n      \"method\": \"Luciferase assays for miRNA-target validation; immunoblotting; siRNA; primary granulosa cells from PCOS patients\",\n      \"journal\": \"Molecular and cellular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct target validation by luciferase with functional cellular phenotype, single lab\",\n      \"pmids\": [\"31173821\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ERβ (ESR2) regulates FATP1/SLC27A1 expression and fatty acid uptake in breast cancer cells; ERβ antagonist (PHTPP) experiments demonstrate that estradiol-induced FATP1 expression and fatty acid uptake are ERβ-dependent\",\n      \"method\": \"ERβ antagonist (PHTPP) pharmacology; gene and protein expression; fatty acid uptake assay in four breast cancer cell lines\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — pharmacological antagonist approach without direct binding or ChIP confirmation, single lab\",\n      \"pmids\": [\"31575907\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ESR2 cooperates with ESR1 and NR5A2 to regulate CYP19A1 (aromatase) expression in chicken theca cells; overexpression of ESR1, ESR2, and NR5A2 upregulates CYP19A1 protein and they mutually restrict each other, forming a regulatory network; ESR2 overexpression in DF-1 cells upregulates CYP19A1 protein\",\n      \"method\": \"Immunofluorescence, western blotting, theca cell culture model, luciferase assays, overexpression in DF-1 cells\",\n      \"journal\": \"General and comparative endocrinology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — overexpression in cell lines without direct binding/ChIP evidence; chicken model with indirect relevance\",\n      \"pmids\": [\"34710471\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"LXA4 activates ESR2 which upregulates LPAR3, leading to Nrf2 activation and inhibition of ferroptosis (via GPX4 upregulation) in fibroblast-like synoviocytes; LPAR3 knockdown reverses the protective effects; ESR2 antagonist (PHTPP) partially reverses the therapeutic effect of exercise on KOA in rats\",\n      \"method\": \"siRNA knockdown of LPAR3; overexpression of LPAR3; PHTPP (ESR2 antagonist) in vivo; GSE29746 dataset analysis; KOA rat model; western blotting; cell co-culture\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockdown/overexpression plus in vivo pharmacological antagonism establishing ESR2/LPAR3/Nrf2 axis, single lab\",\n      \"pmids\": [\"38754271\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ESR2 (estrogen receptor β) is a nuclear receptor that binds estrogen and functions as a ligand-dependent transcription factor by binding estrogen response elements (EREs) in target gene promoters and enhancers; it modulates ERα activity (often antagonistically), directly regulates reproductive processes including primordial follicle quiescence and ovulation-related gene expression in granulosa cells (notably Kiss1), suppresses cell proliferation and invasion in breast cancer cells, controls cortical neuronal migration during brain development, dampens cardiac hypertrophy via inhibition of Ca²⁺-calcineurin-NFAT signaling, suppresses inflammatory NF-κB signaling in macrophages, and regulates circadian activity patterns and synaptic plasticity through downstream miRNA and BDNF pathways.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll classify each paper and extract discoveries only from KEEP papers.\n\n**Classification summary:**\n- Papers about REV-ERB (NR1D1/NR1D2), c-erb-A (thyroid receptor), c-erb-B (HER receptor tyrosine kinases), Erb-B2/B4, ERK, Arabidopsis ESR1/ESR2 (plant transcription factors), zebrafish Erb signaling, general interactome studies, ACTR/coactivator studies not specific to ESR2 → EXCLUDE\n- Papers about ESR2 (estrogen receptor beta, ERβ) canonical protein → KEEP\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"ESR2 (ERβ) was identified as a novel estrogen receptor with high conservation in the DNA-binding domain (96%) and ligand-binding domain (58%) relative to ERα. Ligand-binding experiments confirmed 17β-estradiol binding, and transient transfection with an ERE-based reporter demonstrated estradiol-dependent transactivation. ICI-164384 (ERα antagonist) also antagonizes ERβ.\",\n      \"method\": \"Degenerate PCR cloning, ligand-binding assay, transient transfection/reporter assay\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — original cloning with functional validation by ligand binding and transactivation assay; foundational paper >1800 citations\",\n      \"pmids\": [\"8769313\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The human ESR2 gene was mapped to a distinct chromosomal locus from ESR1, confirming two independent ER genes exist in humans. ESR2 is expressed in multiple tissues including ovarian granulosa cells and developing spermatids of the testis.\",\n      \"method\": \"Genomic cloning, chromosomal localization, Northern blot, in situ hybridization\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (genomic mapping, expression analysis) in foundational gene characterization paper\",\n      \"pmids\": [\"9398750\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Multiple ESR2 (ERβ) isoforms (ERβ1–5) were identified, all diverging within the predicted helix 10 of the ligand-binding domain due to differential exon usage. In vitro band-shift studies showed isoforms form DNA-binding homodimers and heterodimers with each other and with ERα.\",\n      \"method\": \"cDNA library screening, RT-PCR, in vitro gel-shift (EMSA)\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reconstitution of DNA-binding complexes by EMSA combined with molecular cloning; replicated independently\",\n      \"pmids\": [\"9636657\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Full-length human ESR2 (hERβ) was cloned from testis, encoding 53 additional N-terminal amino acids. ERα–ERβ protein interaction was demonstrated in vitro by GST pull-down assay and in vivo by co-immunoprecipitation, showing that ERα and ERβ can interact and cross-signal each other.\",\n      \"method\": \"cDNA cloning, GST pull-down assay, co-immunoprecipitation\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reciprocal in vitro and in vivo interaction assays confirming ERα/ERβ heterodimerization\",\n      \"pmids\": [\"9473491\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"A novel ESR2 isoform, ERβcx, was identified that lacks ligand-binding ability (Kd unmeasurable vs ERβ Kd ~0.6 nM for E2), cannot bind ERE in gel-shift assays, and preferentially heterodimerizes with ERα rather than ERβ, acting as a dominant negative inhibitor of ERα transactivation.\",\n      \"method\": \"Molecular cloning/alternative splicing characterization, ligand-binding assay, EMSA, transient transfection/reporter assay\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal biochemical assays (binding, EMSA, transactivation) demonstrating dominant-negative mechanism\",\n      \"pmids\": [\"9671811\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"ERβ contains a functional AF-2 domain but lacks a strong AF-1; instead its N-terminus harbors a repressor domain. ERβ functions as a transdominant inhibitor of ERα transcriptional activity at subsaturating hormone levels by forming ERα/ERβ heterodimers. ERβ abolishes the partial agonist activity of tamoxifen observed through ERα and decreases overall cellular sensitivity to estradiol. ERβ also interacts with target gene promoters in a ligand-independent manner.\",\n      \"method\": \"Domain deletion/chimeric receptor analysis, transient transfection/reporter assay, co-immunoprecipitation (heterodimer detection), chromatin binding assay\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including mutagenesis and co-IP; highly cited foundational mechanistic study\",\n      \"pmids\": [\"10579320\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"The activated dioxin receptor (AhR/Arnt heterodimer) directly associates with both ERα and ERβ. This association recruits unliganded ER and co-activator p300 to estrogen-responsive gene promoters, activating transcription. Oestrogenic actions of AhR agonists were absent in AhR−/− or ERα−/− ovariectomized mice, establishing the molecular mechanism by which dioxins exert estrogenic effects through ER.\",\n      \"method\": \"Co-immunoprecipitation, chromatin immunoprecipitation, reporter assay, knockout mouse model\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including in vivo KO validation; highly cited mechanistic study\",\n      \"pmids\": [\"12774124\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"In BERKO (ERβ knockout) mice, the immature uterus shows elevated progesterone receptor and Ki-67 levels and exaggerated responsiveness to 17β-estradiol, including enlarged lumen, increased secretion, and enhanced induction of VEGF, IGF-1, complement C3, and IL-1β. E2 failed to downregulate PR in the luminal epithelium of BERKO mice. These findings establish ERβ as a modulator of ERα activity and as having an antiproliferative function in the uterus.\",\n      \"method\": \"ERβ knockout mouse model, immunohistochemistry, ELISA, quantitative gene expression\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function mouse model with multiple specific molecular phenotypic readouts\",\n      \"pmids\": [\"10823946\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"ERβ and ERα physically interact with Sp1 protein (demonstrated by co-immunoprecipitation and pull-down assays) and bind preferentially to the C-terminal region of Sp1. ERβ/Sp1-mediated transcriptional activation at GC-rich promoter elements is ligand- and cell-context-dependent. Domain-swap experiments showed the ERα AF-1 domain (aa 79–117) is specifically required for activation at Sp1 elements, independently of ER subtype context.\",\n      \"method\": \"Co-immunoprecipitation, GST pull-down, chimeric receptor/deletion analysis, luciferase reporter assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reconstitution of ER-Sp1 complex with domain mutagenesis and functional validation\",\n      \"pmids\": [\"10681512\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"ERβ, when expressed in androgen receptor (AR)-positive LNCaP prostate cancer cells, associates with AR and Src upon steroid stimulation, triggering the Src/Raf-1/Erk-2 pathway. Src SH3 domain interacts with a proline-rich stretch of AR; Src SH2 domain interacts with phosphotyrosine 537 of ERα (and analogous site of ERβ). Microinjection of dominant-negative Src abolishes steroid-stimulated S-phase entry, demonstrating that steroid-receptor/Src complexes are required for proliferative signaling.\",\n      \"method\": \"Co-immunoprecipitation, GST fusion pull-down, microinjection of dominant-negative constructs, BrdU S-phase entry assay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reconstitution of protein complex with functional mutagenesis and microinjection rescue; highly cited\",\n      \"pmids\": [\"11032808\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"ERβ expressed via adenoviral vector in ER-negative MDA-MB-231 breast cancer cells localizes to the nucleus, transactivates ERE reporter constructs in the presence of E2, and inhibits cell proliferation in a ligand-independent manner. ERβ (unlike ERα) cannot regulate c-myc expression but induces p21 (CDKN1A). Both ERα and ERβ decrease cell motility and invasion.\",\n      \"method\": \"Adenoviral overexpression, immunocytochemistry, RT-PCR, Western blot, proliferation assay, invasion assay, reporter assay\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct gain-of-function in defined cell system with multiple orthogonal readouts\",\n      \"pmids\": [\"11517191\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"ERβ opposes ERα at the cyclin D1 promoter: ERα activates cyclin D1 gene transcription via both a CRE element at −57 and an AP-1 site at −954, while ERβ inhibits cyclin D1 expression in the presence of estrogens (activates only with antiestrogens). ERβ completely dominates over ERα or superactive ERαK206A in blocking estrogen/ERα-mediated cyclin D1 induction.\",\n      \"method\": \"Luciferase reporter assay with CRE/AP-1 site mutants, Western blot for endogenous cyclin D1, chimeric receptor analysis in HeLa cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — promoter dissection with mutagenesis and endogenous protein validation; highly cited\",\n      \"pmids\": [\"11986316\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ERβ is essential for late embryonic brain development. ERβ knockout mice show smaller brains at E18.5 with fewer cortical neurons. BrdU labeling experiments demonstrated a defect in neuronal migration (fewer BrdUrd-labeled cells in superficial cortical layers by E18.5/P14 when labeled at E14.5–E16.5) and increased apoptosis in the ventricular zone. Radial glia processes guiding migrating neurons were fragmented in ERβ-null mice.\",\n      \"method\": \"ERβ knockout mouse model, BrdU birth-dating/migration assay, TUNEL apoptosis assay, immunofluorescence of radial glia\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with multiple orthogonal assays establishing specific mechanistic defects in neuronal migration and survival\",\n      \"pmids\": [\"12515851\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ERβ expression in ERα-positive MCF-7 breast cancer cells causes G2 cell cycle arrest and inhibits tumor formation in mouse xenografts. ERβ represses transcription of c-myc, cyclin D1, and cyclin A, while increasing p21(Cip1) and p27(Kip1). This is opposite to ERα, which promotes proliferation and tumor formation.\",\n      \"method\": \"Adenoviral ERβ expression, flow cytometry (cell cycle), mouse xenograft model, RT-PCR/Western blot for cell cycle genes\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — gain-of-function with in vivo xenograft validation and defined molecular mechanism; highly cited\",\n      \"pmids\": [\"14729654\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Induced ERβ expression in T47D breast cancer cells reduces 17β-estradiol-stimulated proliferation when ERβ mRNA equals ERα levels. ERβ decreases cyclin E, Cdc25A, p45(Skp2), reduces Cdk2 kinase activity, and increases p27(Kip1), suggesting ERβ acts on the G1-phase cell-cycle machinery to oppose ERα-driven proliferation.\",\n      \"method\": \"Inducible ERβ expression system, proliferation assay, Western blot, Cdk2 kinase activity assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — inducible expression with kinase activity assay and defined cell-cycle pathway placement\",\n      \"pmids\": [\"14745018\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ERβ localizes primarily to mitochondria, not to the nucleus, in rat primary neurons, primary cardiomyocytes, and a murine hippocampal cell line. This was established by immunocytochemistry with two independent ERβ antibodies co-localized with mitochondrial markers, immunoblotting of purified human heart mitochondria, and mass spectrometric identification of seven ERβ tryptic fragments in the mitochondrial fraction. No nuclear translocation of ERβ occurred upon 17β-estradiol treatment.\",\n      \"method\": \"Immunocytochemistry, confocal microscopy, subcellular fractionation, immunoblotting of purified mitochondria, MALDI mass spectrometry\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including proteomics and purified organelle fractionation; highly cited\",\n      \"pmids\": [\"15024130\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"ERβ isoforms 2, 4, and 5 do not bind ligand with full activity, cannot form homodimers, and have no innate transcriptional activity due to structural differences in their C-terminus (disrupted helix 12). However, they can heterodimerize with ERβ1 and enhance ERβ1 transactivation in a ligand-dependent manner. ERβ1 is the obligatory active partner; a single functional helix 12 in a dimer is sufficient for gene transactivation. ERβ1 preferentially forms heterodimers with other isoforms under estrogen (but not phytoestrogen) stimulation.\",\n      \"method\": \"Molecular modeling, co-immunoprecipitation (dimerization), luciferase reporter assay, ligand-binding assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — structural modeling validated by functional assays showing isoform-specific dimerization and transactivation\",\n      \"pmids\": [\"16938840\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Activation of ESR2 (ERβ) in vivo by the selective agonist 8β-VE2 in ovariectomized spontaneously hypertensive rats lowers systolic blood pressure (−38 mmHg), reduces peripheral vascular resistance, enhances aortic ERβ expression, improves NO-dependent vasorelaxation, augments phosphorylation of vasodilator-stimulated phosphoprotein in isolated aortic rings, and attenuates cardiac hypertrophy without uterotrophic effects.\",\n      \"method\": \"In vivo pharmacological agonist administration, echocardiography, vascular ring relaxation assay, Western blot, immunohistochemistry\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — selective ERβ agonist in vivo with multiple functional cardiovascular readouts; single lab\",\n      \"pmids\": [\"18056768\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"AP-2α and AP-2γ (but not AP-2β) regulate ESR2 transcription by binding to the 0N promoter at a methylation hotspot (center 1, a 16-bp AP-2 binding site). ChIP confirmed AP-2α occupancy. Forced AP-2α/γ expression increased ERβ mRNA; siRNA knockdown reduced it. ERβ transcript levels correlate with AP-2α/γ levels across PCa cell lines.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), promoter deletion/reporter assay, siRNA knockdown, RT-PCR, forced expression\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — ChIP plus mutagenesis plus siRNA plus forced expression establishes ESR2 as AP-2-regulated gene\",\n      \"pmids\": [\"17525739\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ERβ inhibits ERα-mediated induction of progesterone receptor in the neonatal rat ventromedial nucleus of the hypothalamus in an anatomically specific manner. Selective ERα activation in the relative absence of ERβ induces greater PR expression; selective ERβ activation attenuates this ERα-mediated increase in the ventromedial nucleus but not the medial preoptic nucleus, despite high ERα expression in both regions.\",\n      \"method\": \"Selective ER agonist administration in vivo, in situ hybridization/immunohistochemistry for PR as functional readout\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — selective agonists with anatomically resolved functional readout; single lab\",\n      \"pmids\": [\"18511514\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The selective ERβ agonist ERB-041 inhibits LPS-induced iNOS expression in peritoneal macrophages from endometriosis patients by preventing nuclear translocation of NF-κB p65, without affecting the ERK pathway. ERβ (not ERα) is the predominant ER subtype in these macrophages. ERKs are involved in LPS-induced iNOS but are not repressed by ERβ activation.\",\n      \"method\": \"RT-PCR, immunoblot, pharmacological agonist treatment, nuclear fractionation (NF-κB translocation), ERK inhibitor (U0126)\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — selective agonist with pathway dissection using inhibitors; single lab, moderate evidence\",\n      \"pmids\": [\"19447495\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Com-1/P8 protein physically interacts with ERβ in breast cancer cells as demonstrated by reciprocal co-immunoprecipitation. Both proteins co-localize in the nucleus. 17β-estradiol stimulation reduces nuclear Com-1 staining, and this reduction is reversed by ubiquitin/proteasome inhibitors (ubiquitin aldehyde, lactacystin), indicating that the ubiquitin-proteasome pathway regulates the Com-1/ERβ complex. Elimination of Com-1 leads to increased estradiol-stimulated growth in ER-negative/ERβ-positive cells.\",\n      \"method\": \"Reciprocal co-immunoprecipitation, immunocytochemistry, proteasome inhibitor treatment, ribozyme transgene knockdown, proliferation assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — reciprocal Co-IP plus functional assay; single lab\",\n      \"pmids\": [\"15781258\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In adult male rats, ESR2-selective agonist administration reduces sperm counts due to spermiation failure (defects in tubulobulbar complex formation caused by decreased expression of actin remodeling genes) and increased spermatocyte apoptosis associated with elevated oxidative stress and decreased anti-apoptotic gene transcripts. ESR1 agonist causes arrest of round-to-elongated spermatid differentiation. The two receptors regulate distinct aspects of spermatogenesis.\",\n      \"method\": \"In vivo selective ESR agonist administration, histology, gene expression analysis, sperm count, oxidative stress assay\",\n      \"journal\": \"Molecular and cellular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — selective receptor agonists in vivo with multiple cellular and molecular readouts distinguishing ESR1 vs ESR2 roles\",\n      \"pmids\": [\"27004961\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"E2/ERβ suppresses ISO-induced cardiac cellular hypertrophy in H9c2 cardiomyoblasts by inhibiting Ca2+-calcineurin signaling. ERβ overexpression and/or E2 inhibits ISO-induced elevation of p-CaMKII, calcineurin, p-GATA4, NFATc3, ANP, and BNP. Mechanistically, E2/ERβ suppresses Ca2+ influx, inhibits calcineurin activity to activate I-1 protein, suppresses PP1, then induces PLB phosphorylation and activation, resulting in Ca2+ reuptake into the sarcoplasmic reticulum. NFATc3 nuclear translocation is also inhibited. Calcineurin inhibitor (CsA) confirmed calcineurin as key mediator; Ca2+ chelator (BAPTA) blocked E2/ERβ effects.\",\n      \"method\": \"ERβ overexpression, calcineurin inhibitor (CsA), Ca2+ chelator (BAPTA), Western blot for signaling cascade proteins, immunofluorescence (NFATc3 localization), cell size measurement\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pathway dissection with pharmacological inhibitors and overexpression; single lab, multiple mechanistic readouts\",\n      \"pmids\": [\"28863192\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ESR2 is required for gonadotropin-induced follicle maturation and ovulation in rats. RNA-seq of granulosa cells from Esr2-null and Esr2-DBD mutant rats identified 1,696 differentially expressed genes enriched in steroidogenesis, follicle maturation, and ovulation pathways. Kiss1 was identified as a key ESR2-regulated gene in granulosa cells, indicating an intra-follicular role distinct from hypothalamic Kiss1 regulation by ESR1.\",\n      \"method\": \"Esr2-null and DNA-binding domain mutant rat models, RNA-sequencing of granulosa cells, molecular pathway analysis, exogenous gonadotropin stimulation\",\n      \"journal\": \"Molecular and cellular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — two genetic models (null and DBD mutant) with genome-wide transcriptome in specific cell type\",\n      \"pmids\": [\"29580824\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ESR2 directly regulates Kiss1 expression in granulosa cells. The Kiss1 promoter, upstream enhancer, and downstream enhancer possess conserved EREs with active histone marks in gonadotropin-stimulated granulosa cells. ChIP revealed ESR2 binding enrichment at these regulatory regions. ERE mutation in the Kiss1 promoter blocked ESR2-mediated induction. Gonadotropins induce ERK2-mediated ESR2 phosphorylation and upregulate AP-1 factors (FOSL2, JUNB), which synergistically activate the Kiss1 promoter with ESR2.\",\n      \"method\": \"ChIP, ERE mutagenesis/reporter assay, ESR2 overexpression, kinase activity assay (ERK2-ESR2 phosphorylation), immunoblot, PMSG/hCG gonadotropin stimulation\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — ChIP, mutagenesis, and phosphorylation assay establishing ESR2-ERE-AP1 co-regulation of Kiss1\",\n      \"pmids\": [\"30277501\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Biallelic (c.541_543del p.Asn181del, in the DNA-binding domain) and monoallelic (p.Gly84Val in N-terminus; p.Leu426Arg in ligand-binding domain) ESR2 variants were identified in 46,XY DSD patients. Luciferase assays showed significantly increased transcriptional activation for the p.Asn181del and p.Leu426Arg variants, and protein structure analysis demonstrated impact on protein conformation. ERβ immunostaining confirmed expression in the developing human male embryo intestine and eyes.\",\n      \"method\": \"Whole-exome sequencing, luciferase transactivation assay, protein structure analysis, immunostaining of human embryo\",\n      \"journal\": \"Genetics in medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional variant characterization with reporter assay and structural analysis; novel disease gene identification\",\n      \"pmids\": [\"29261182\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"miR-186 and miR-135a directly repress ESR2 expression in granulosa cells, verified by luciferase assays and immunoblotting. Reduced ESR2 further inhibits CDKN1A (p21) expression, promoting granulosa cell proliferation and suppressing apoptosis. Estradiol treatment directly increases miR-186 and miR-135a levels in granulosa cells, creating a feedback loop relevant to PCOS pathophysiology.\",\n      \"method\": \"Luciferase 3'UTR reporter assay, immunoblotting, miRNA overexpression/inhibition, primary granulosa cell culture\",\n      \"journal\": \"Molecular and cellular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct target validation by luciferase assay plus functional downstream (CDKN1A) assessment; single lab\",\n      \"pmids\": [\"31173821\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ESR2 (ERβ) acts as a gatekeeper to maintain the primordial follicle reserve. Esr2-null rats show increased primordial follicle activation, premature ovarian senescence, and reduced serum AMH/estradiol. ESR2-selective antagonist PHTPP increases follicle activation in wild-type rats; DPN (selective agonist) decreases it. ESR1 deletion does not increase follicle activation, confirming ESR2-specific regulation. Esr2 DBD mutants also show increased activation, indicating requirement for canonical transcriptional function. Loss of ESR2 augments AKT, ERK, and mTOR pathway activation in both granulosa cells and oocytes.\",\n      \"method\": \"Esr2-null and DBD-mutant rat models, selective agonist/antagonist pharmacology, follicle counting histology, serum hormone ELISA, Western blot for AKT/ERK/mTOR signaling\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — two genetic models plus pharmacological validation with multiple pathway readouts; pathway placement via signaling analysis\",\n      \"pmids\": [\"32141511\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Complete deletion of all Esr2 exons in mice (Esr2ΔE1-10 via CRISPR/Cas9) establishes that female ERβ-null mice are subfertile at young age and become infertile by ~6 months, with smaller ovaries, very few corpora lutea (indicating ovulation failure), and reduced diestrus estradiol levels. Male Esr2ΔE1-10 mice are fertile. This confirms ERβ's essential role in female reproduction likely through regulation of serum estradiol levels.\",\n      \"method\": \"CRISPR/Cas9 all-exon deletion, fertility assessment (litter number/size), ovarian histology/corpora lutea counting, serum estradiol measurement\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — complete gene deletion with rigorous phenotypic characterization; cleaner model than prior partial-exon knockouts\",\n      \"pmids\": [\"32703416\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ERβ (ER-β) regulates FATP1/SLC27A1 expression in breast cancer cells. Experiments with estradiol and PHTPP (ERβ antagonist) demonstrated that ERβ regulates FATP1 mRNA expression, fatty acid uptake, and cell viability in four breast cancer cell lines. Inhibition of FATP1 with arylpiperazine 5k interfered with fatty acid uptake and cell viability.\",\n      \"method\": \"ERβ antagonist (PHTPP) pharmacology, RT-PCR, fatty acid uptake assay, cell viability assay, FATP1 inhibitor\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — pharmacological approach (no genetic KO/KD of ESR2) with multiple cell lines; single lab\",\n      \"pmids\": [\"31575907\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ESR2-mediated estrogen signaling impairs glycemic homeostasis, antagonizing the beneficial effects of ESR1. In Esr2 transgenic mice, GLUT4 (SLC2A4) expression and translocation are reduced. ESR2 acts as a negative regulator of Slc2a4 transcription by genomic mechanisms involving cooperation with other transcription factors, and estradiol-induced ESR2 activation is associated with detrimental effects on glucose metabolism.\",\n      \"method\": \"Transgenic mouse models (Esr1/Esr2 knockout/overexpression), GLUT4 expression/translocation assays, Slc2a4 promoter analysis, glucose homeostasis measurements\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — transgenic mouse models with mechanistic gene regulation analysis; review integrating multiple studies\",\n      \"pmids\": [\"33430527\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ESR2 acts as a negative transcription factor that downregulates miR-10a transcription in the prefrontal cortex; miR-10a-5p in turn suppresses BDNF expression. This ESR2→miR-10a-5p⊣BDNF axis contributes to postpartum depression by affecting synaptic plasticity (alterations in SYP, SYN, PSD95, and glutamate receptor expression). Bioinformatics prediction, in vivo animal behavioral studies, cell transfection, and primary neuron culture confirmed the molecular triad. Stereotactic/intranasal antagomir or BDNF administration rescued depressive-like behavior.\",\n      \"method\": \"Bioinformatics, in vivo behavioral assays, cell transfection, luciferase reporter assay, primary neuron culture, stereotactic/intranasal drug delivery\",\n      \"journal\": \"Research (Washington, D.C.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple in vivo and in vitro methods establishing ESR2-miRNA-BDNF pathway; single lab\",\n      \"pmids\": [\"39588356\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"LXA4 activates ESR2 in fibroblast-like synoviocytes (FLSs) to inhibit ferroptosis via upregulation of LPAR3, which in turn activates the Nrf2/GPX4/SOD1 axis. LPAR3 overexpression upregulated GPX4, Nrf2, SOD1 and downregulated MMP13/MMP3; LPAR3 knockdown reversed these effects. ESR2-selective antagonist PHTPP partially reversed the improvement in synovial and cartilage pathology induced by exercise in KOA rats, confirming ESR2 involvement in this protective pathway.\",\n      \"method\": \"Cell co-culture, LPAR3 overexpression/knockdown, Western blot, in vivo KOA rat model with PHTPP antagonist, dataset analysis (GSE29746)\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss and gain of function for downstream target (LPAR3) plus in vivo ESR2 antagonism; single lab\",\n      \"pmids\": [\"38754271\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In chicken ovarian theca cells, ESR2 (along with ESR1 and NR5A2) forms a functional transcriptional network regulating CYP19A1 (aromatase) expression. Overexpression of ESR1, ESR2, and NR5A2 in DF-1 cells upregulates CYP19A1 protein and the three factors mutually restrict each other. ESR2 participates in cross-talk regulating theca cell CYP19A1 expression.\",\n      \"method\": \"Immunofluorescence, Western blot, theca cell culture model, luciferase promoter assay, overexpression in DF-1 cells\",\n      \"journal\": \"General and comparative endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple methods in avian ortholog context; ortholog finding relevant to mammalian ESR2 function in steroidogenesis\",\n      \"pmids\": [\"34710471\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ESR2 (estrogen receptor beta, ERβ) is a ligand-activated nuclear receptor that forms homodimers and heterodimers with ERα (and with inactive ERβ isoforms), binds estrogen response elements to regulate transcription, and broadly functions as a dominant negative modulator of ERα activity—repressing cyclin D1, c-myc, and cell cycle progression while inducing p21/p27 to cause G2 arrest—while additionally localizing to mitochondria, suppressing NF-κB-mediated inflammation via non-genomic mechanisms, activating Src/ERK signaling through steroid receptor/Src complexes, regulating primordial follicle activation and ovulation through canonical transcriptional activity in granulosa cells, and participating in neuronal migration, cardiovascular protection, spermatogenesis, and glycemic homeostasis.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ESR2 (estrogen receptor β) is a ligand-dependent nuclear receptor transcription factor that binds estrogen response elements to regulate target genes governing reproduction, neural development, cardiovascular homeostasis, and inflammation. In the ovary, ESR2 is essential for maintaining primordial follicle quiescence by suppressing AKT/ERK/mTOR signaling, for gonadotropin-induced expression of ovulation genes including Kiss1 via ERE binding and cooperation with MAPK-phosphorylated AP-1 factors, and its loss causes anovulation and progressive female infertility [PMID:32141511, PMID:30277501, PMID:32703416]. ESR2 antagonizes ERα-driven proliferative signaling in the uterus and breast cancer cells, inhibits NF-κB-mediated inflammatory responses in macrophages, suppresses cardiac hypertrophy through inhibition of Ca²⁺-calcineurin-NFAT signaling, and is required for cortical neuronal migration during embryonic brain development [PMID:10823946, PMID:11517191, PMID:19447495, PMID:28863192, PMID:12515851]. Variants in the ESR2 DNA-binding and ligand-binding domains have been identified in patients with 46,XY disorders of sex development, with functional assays demonstrating altered transcriptional activity [PMID:29261182].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"ERβ knockout mice revealed that ESR2 functions as an antiproliferative modulator of ERα in the uterus, establishing that the two estrogen receptors have opposing rather than redundant roles in reproductive tissue.\",\n      \"evidence\": \"ERβ knockout (BERKO) mouse model with histology, immunohistochemistry, and gene expression of PR and Ki-67\",\n      \"pmids\": [\"10823946\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism of ERα antagonism not defined\", \"Whether ESR2 directly represses ERα target genes or acts indirectly was unknown\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Reconstitution of ERβ in ER-negative breast cancer cells demonstrated that ESR2 is a nuclear transcription factor that suppresses proliferation and invasion independently of ligand, distinguishing its antiproliferative function from ERα.\",\n      \"evidence\": \"Adenoviral re-expression of ERβ in MDA-MB-231 cells with reporter, proliferation, and invasion assays\",\n      \"pmids\": [\"11517191\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ligand-independent mechanism of growth suppression not molecularly defined\", \"Relevance to in vivo tumor suppression not established\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"ERβ knockout mice revealed a requirement for ESR2 in cortical neuronal migration and survival during late embryogenesis, extending the receptor's function beyond reproductive tissues to brain development.\",\n      \"evidence\": \"ERβ knockout mice with BrdU pulse-chase at E12.5/E14.5, immunohistochemistry for apoptosis and radial glia at E18.5\",\n      \"pmids\": [\"12515851\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets mediating neuronal migration unknown\", \"Whether the phenotype is cell-autonomous in neurons vs. radial glia was not resolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Selective ERβ agonist treatment demonstrated that ESR2 activation lowers blood pressure and attenuates cardiac hypertrophy via NO-dependent vasorelaxation, establishing a cardiovascular protective role distinct from ERα.\",\n      \"evidence\": \"12-week treatment with 8β-VE2 in ovariectomized SHR; echocardiography, aortic ring studies, phospho-VASP immunoblotting\",\n      \"pmids\": [\"18056768\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Selectivity of agonist not independently confirmed\", \"Downstream transcriptional program in cardiomyocytes/vascular cells not mapped\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"AP-2α and AP-2γ were identified as direct transcriptional regulators of the ESR2 0N promoter, revealing how ESR2 expression itself is controlled at a methylation-sensitive regulatory region.\",\n      \"evidence\": \"ChIP, luciferase reporter deletion analysis, forced expression and siRNA knockdown of AP-2 in prostate cancer cells\",\n      \"pmids\": [\"17525739\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether AP-2 regulation of ESR2 is tissue-specific beyond prostate cells not tested\", \"Relationship between methylation and AP-2 binding not fully dissected\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"ESR2 activation was shown to suppress NF-κB nuclear translocation in macrophages, providing a molecular mechanism for its anti-inflammatory activity independent of ERK signaling.\",\n      \"evidence\": \"Selective ERβ agonist ERB-041 on LPS-stimulated peritoneal macrophages; nuclear fractionation, immunoblot for p65 and iNOS\",\n      \"pmids\": [\"19447495\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct physical interaction between ERβ and NF-κB pathway components not shown\", \"Whether ESR2 binds chromatin at inflammatory gene loci not tested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"ERβ variants in the DNA-binding and ligand-binding domains were linked to 46,XY disorders of sex development, with functional assays showing altered transcriptional activity, establishing ESR2 as a DSD-associated gene.\",\n      \"evidence\": \"Whole-exome sequencing of DSD patients; luciferase transcriptional activation assays; protein structure analysis; human embryonic gonad immunostaining\",\n      \"pmids\": [\"29261182\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Small patient numbers; independent replication in additional DSD cohorts needed\", \"Whether gain-of-function (p.Asn181del) or loss-of-function explains the phenotype not fully resolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"The anti-hypertrophic mechanism of ESR2 in cardiomyocytes was molecularly defined: ERβ activates inhibitor-1 to suppress PP1, promoting phospholamban phosphorylation and Ca²⁺ reuptake, thereby blocking calcineurin-NFAT signaling.\",\n      \"evidence\": \"ERβ overexpression in H9c2 cardiomyoblasts; isoproterenol stimulation; calcineurin inhibitor and Ca²⁺ chelator controls; immunoblotting for CaMKII, calcineurin, GATA4, NFATc3\",\n      \"pmids\": [\"28863192\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Overexpression system; endogenous ERβ levels in cardiomyocytes may differ\", \"In vivo cardiac-specific knockout not performed\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Using null and DBD-mutant rat models, ESR2's DNA-binding-dependent transcriptional activity was shown to be essential for ovulation and granulosa cell gene expression, including direct regulation of Kiss1 through ERE binding and cooperation with MAPK-activated AP-1 factors.\",\n      \"evidence\": \"Esr2 null and DBD-mutant rats; gonadotropin stimulation; RNA-seq of granulosa cells; ChIP for ESR2 at Kiss1 EREs; ERE mutagenesis; ERK inhibition\",\n      \"pmids\": [\"29580824\", \"30277501\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genome-wide ESR2 cistrome in granulosa cells not established by ChIP-seq\", \"Whether FOSL2/JUNB physically complex with ESR2 at chromatin not confirmed by sequential ChIP\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"ESR2 was established as the specific estrogen receptor subtype maintaining primordial follicle quiescence by suppressing AKT/ERK/mTOR activation, and complete gene deletion confirmed progressive female infertility due to ovulatory failure.\",\n      \"evidence\": \"Esr2-null rat with pharmacological rescue (DPN agonist, PHTPP antagonist); CRISPR/Cas9 all-exon Esr2 deletion mouse; follicle counting, phospho-AKT/ERK/mTOR immunoblotting; ESR1-null comparison\",\n      \"pmids\": [\"32141511\", \"32703416\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets mediating follicle quiescence not identified\", \"Whether ESR2 acts in oocytes, granulosa cells, or both for quiescence maintenance not resolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"ESR2 was found to negatively regulate miR-10a transcription in the prefrontal cortex, establishing an ESR2→miR-10a-5p→BDNF axis that modulates synaptic plasticity markers.\",\n      \"evidence\": \"Luciferase assays, in vivo stereotactic and intranasal antagomir delivery, primary neuron culture, western blotting for SYP/SYN/PSD95\",\n      \"pmids\": [\"39588356\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether ESR2 directly binds the miR-10a promoter via ERE not shown by ChIP\", \"Behavioral phenotype specific to postpartum model; generalizability unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A genome-wide ESR2 cistrome across key target tissues (ovary, brain, heart) remains unestablished, and the structural basis for ESR2's antagonism of ERα-driven transcription is not resolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No genome-wide ChIP-seq map of ESR2 binding in granulosa cells, cardiomyocytes, or cortical neurons\", \"Structural mechanism of ERα antagonism unknown\", \"Cell-type-specific co-factor repertoire interacting with ESR2 not defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [8, 9]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [1, 8, 9, 16]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 5, 11]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 9, 14]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0074160\", \"supporting_discovery_ids\": [1, 8, 9, 16]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 5, 7, 11]},\n      {\"term_id\": \"R-HSA-1474165\", \"supporting_discovery_ids\": [8, 11, 12]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [2, 10]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [6]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"ESR1\",\n      \"FOSL2\",\n      \"JUNB\",\n      \"TFAP2A\",\n      \"TFAP2C\",\n      \"NUDT21\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\nWait, I need to correct the pathway term_ids. \"GO:0074160\" is not in the allowed list. Let me fix this:\n\n```json\n{\n  \"mechanistic_narrative\": \"ESR2 (estrogen receptor β) is a ligand-dependent nuclear receptor transcription factor that binds estrogen response elements to regulate target genes governing reproduction, neural development, cardiovascular homeostasis, and inflammation. In the ovary, ESR2 is essential for maintaining primordial follicle quiescence by suppressing AKT/ERK/mTOR signaling, for gonadotropin-induced expression of ovulation genes including Kiss1 via ERE binding and cooperation with MAPK-phosphorylated AP-1 factors, and its loss causes anovulation and progressive female infertility [PMID:32141511, PMID:30277501, PMID:32703416]. ESR2 antagonizes ERα-driven proliferative signaling in the uterus and breast cancer cells, inhibits NF-κB-mediated inflammatory responses in macrophages, suppresses cardiac hypertrophy through inhibition of Ca²⁺-calcineurin-NFAT signaling, and is required for cortical neuronal migration during embryonic brain development [PMID:10823946, PMID:11517191, PMID:19447495, PMID:28863192, PMID:12515851]. Variants in the ESR2 DNA-binding and ligand-binding domains have been identified in patients with 46,XY disorders of sex development, with functional assays demonstrating altered transcriptional activity [PMID:29261182].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"ERβ knockout mice revealed that ESR2 functions as an antiproliferative modulator of ERα in the uterus, establishing that the two estrogen receptors have opposing rather than redundant roles in reproductive tissue.\",\n      \"evidence\": \"ERβ knockout (BERKO) mouse model with histology, immunohistochemistry, and gene expression of PR and Ki-67\",\n      \"pmids\": [\"10823946\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism of ERα antagonism not defined\", \"Whether ESR2 directly represses ERα target genes or acts indirectly was unknown\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Reconstitution of ERβ in ER-negative breast cancer cells demonstrated that ESR2 is a nuclear transcription factor that suppresses proliferation and invasion independently of ligand, distinguishing its antiproliferative function from ERα.\",\n      \"evidence\": \"Adenoviral re-expression of ERβ in MDA-MB-231 cells with reporter, proliferation, and invasion assays\",\n      \"pmids\": [\"11517191\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ligand-independent mechanism of growth suppression not molecularly defined\", \"Relevance to in vivo tumor suppression not established\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"ERβ knockout mice revealed a requirement for ESR2 in cortical neuronal migration and survival during late embryogenesis, extending the receptor's function beyond reproductive tissues to brain development.\",\n      \"evidence\": \"ERβ knockout mice with BrdU pulse-chase at E12.5/E14.5, immunohistochemistry for apoptosis and radial glia at E18.5\",\n      \"pmids\": [\"12515851\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets mediating neuronal migration unknown\", \"Whether the phenotype is cell-autonomous in neurons vs. radial glia was not resolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Selective ERβ agonist treatment demonstrated that ESR2 activation lowers blood pressure and attenuates cardiac hypertrophy via NO-dependent vasorelaxation, establishing a cardiovascular protective role distinct from ERα.\",\n      \"evidence\": \"12-week treatment with 8β-VE2 in ovariectomized SHR; echocardiography, aortic ring studies, phospho-VASP immunoblotting\",\n      \"pmids\": [\"18056768\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Selectivity of agonist not independently confirmed\", \"Downstream transcriptional program in cardiomyocytes/vascular cells not mapped\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"AP-2α and AP-2γ were identified as direct transcriptional regulators of the ESR2 0N promoter, revealing how ESR2 expression itself is controlled at a methylation-sensitive regulatory region.\",\n      \"evidence\": \"ChIP, luciferase reporter deletion analysis, forced expression and siRNA knockdown of AP-2 in prostate cancer cells\",\n      \"pmids\": [\"17525739\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether AP-2 regulation of ESR2 is tissue-specific beyond prostate cells not tested\", \"Relationship between methylation and AP-2 binding not fully dissected\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"ESR2 activation was shown to suppress NF-κB nuclear translocation in macrophages, providing a molecular mechanism for its anti-inflammatory activity independent of ERK signaling.\",\n      \"evidence\": \"Selective ERβ agonist ERB-041 on LPS-stimulated peritoneal macrophages; nuclear fractionation, immunoblot for p65 and iNOS\",\n      \"pmids\": [\"19447495\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct physical interaction between ERβ and NF-κB pathway components not shown\", \"Whether ESR2 binds chromatin at inflammatory gene loci not tested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"ERβ variants in the DNA-binding and ligand-binding domains were linked to 46,XY disorders of sex development, with functional assays showing altered transcriptional activity, establishing ESR2 as a DSD-associated gene.\",\n      \"evidence\": \"Whole-exome sequencing of DSD patients; luciferase transcriptional activation assays; protein structure analysis; human embryonic gonad immunostaining\",\n      \"pmids\": [\"29261182\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Small patient numbers; independent replication in additional DSD cohorts needed\", \"Whether gain-of-function (p.Asn181del) or loss-of-function explains the phenotype not fully resolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"The anti-hypertrophic mechanism of ESR2 in cardiomyocytes was molecularly defined: ERβ activates inhibitor-1 to suppress PP1, promoting phospholamban phosphorylation and Ca²⁺ reuptake, thereby blocking calcineurin-NFAT signaling.\",\n      \"evidence\": \"ERβ overexpression in H9c2 cardiomyoblasts; isoproterenol stimulation; calcineurin inhibitor and Ca²⁺ chelator controls; immunoblotting for CaMKII, calcineurin, GATA4, NFATc3\",\n      \"pmids\": [\"28863192\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Overexpression system; endogenous ERβ levels in cardiomyocytes may differ\", \"In vivo cardiac-specific knockout not performed\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Using null and DBD-mutant rat models, ESR2's DNA-binding-dependent transcriptional activity was shown to be essential for ovulation and granulosa cell gene expression, including direct regulation of Kiss1 through ERE binding and cooperation with MAPK-activated AP-1 factors.\",\n      \"evidence\": \"Esr2 null and DBD-mutant rats; gonadotropin stimulation; RNA-seq of granulosa cells; ChIP for ESR2 at Kiss1 EREs; ERE mutagenesis; ERK inhibition\",\n      \"pmids\": [\"29580824\", \"30277501\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genome-wide ESR2 cistrome in granulosa cells not established by ChIP-seq\", \"Whether FOSL2/JUNB physically complex with ESR2 at chromatin not confirmed by sequential ChIP\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"ESR2 was established as the specific estrogen receptor subtype maintaining primordial follicle quiescence by suppressing AKT/ERK/mTOR activation, and complete gene deletion confirmed progressive female infertility due to ovulatory failure.\",\n      \"evidence\": \"Esr2-null rat with pharmacological rescue (DPN agonist, PHTPP antagonist); CRISPR/Cas9 all-exon Esr2 deletion mouse; follicle counting, phospho-AKT/ERK/mTOR immunoblotting; ESR1-null comparison\",\n      \"pmids\": [\"32141511\", \"32703416\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets mediating follicle quiescence not identified\", \"Whether ESR2 acts in oocytes, granulosa cells, or both for quiescence maintenance not resolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"ESR2 was found to negatively regulate miR-10a transcription in the prefrontal cortex, establishing an ESR2→miR-10a-5p→BDNF axis that modulates synaptic plasticity markers.\",\n      \"evidence\": \"Luciferase assays, in vivo stereotactic and intranasal antagomir delivery, primary neuron culture, western blotting for SYP/SYN/PSD95\",\n      \"pmids\": [\"39588356\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether ESR2 directly binds the miR-10a promoter via ERE not shown by ChIP\", \"Behavioral phenotype specific to postpartum model; generalizability unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A genome-wide ESR2 cistrome across key target tissues (ovary, brain, heart) remains unestablished, and the structural basis for ESR2's antagonism of ERα-driven transcription is not resolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No genome-wide ChIP-seq map of ESR2 binding in granulosa cells, cardiomyocytes, or cortical neurons\", \"Structural mechanism of ERα antagonism unknown\", \"Cell-type-specific co-factor repertoire interacting with ESR2 not defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [8, 9]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [1, 8, 9, 16]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 5, 11]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 9, 14]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [1, 8, 9, 16]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 5, 7, 11]},\n      {\"term_id\": \"R-HSA-1474165\", \"supporting_discovery_ids\": [8, 11, 12]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [2, 10]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [6]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"ESR1\",\n      \"FOSL2\",\n      \"JUNB\",\n      \"TFAP2A\",\n      \"TFAP2C\",\n      \"NUDT21\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"ESR2 (estrogen receptor beta) is a ligand-activated nuclear receptor that binds 17β-estradiol via a conserved ligand-binding domain and regulates transcription through estrogen response elements (EREs), functioning broadly as an antiproliferative modulator of estrogen signaling that opposes ERα-driven cell cycle progression [PMID:8769313, PMID:10579320, PMID:14729654]. ESR2 heterodimerizes with ERα and with its own splice isoforms—some of which (e.g., ERβcx) lack ligand binding and act as dominant-negative inhibitors of ERα—to repress cyclin D1 and c-myc while inducing p21 and p27, causing G2 arrest and suppressing tumor growth in breast cancer xenografts [PMID:9671811, PMID:11986316, PMID:14729654, PMID:14745018]. Beyond its antiproliferative genomic activity, ESR2 localizes to mitochondria in neurons and cardiomyocytes, activates non-genomic Src/ERK signaling through steroid receptor complexes, suppresses NF-κB nuclear translocation to inhibit inflammation, and protects against cardiac hypertrophy via inhibition of Ca²⁺-calcineurin signaling [PMID:15024130, PMID:11032808, PMID:19447495, PMID:28863192]. ESR2 is essential for female fertility—maintaining the primordial follicle reserve by restraining AKT/mTOR activation and regulating Kiss1 and CYP19A1 in granulosa cells—and is required for embryonic cortical neuronal migration and late brain development [PMID:32141511, PMID:30277501, PMID:12515851, PMID:32703416].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"The discovery of a second estrogen receptor (ERβ) established that estrogen signaling operates through two independent receptors with conserved DNA-binding but divergent ligand-binding domains, raising the question of whether ERβ has distinct or redundant functions relative to ERα.\",\n      \"evidence\": \"Degenerate PCR cloning from rat prostate, ligand-binding assay, ERE-reporter transactivation in transfected cells\",\n      \"pmids\": [\"8769313\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue-specific functions of ERβ versus ERα not yet defined\", \"Endogenous target genes unknown\", \"In vivo role not established\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Identification of multiple ERβ splice isoforms and demonstration of ERα–ERβ heterodimerization revealed that ERβ could modulate ERα activity through combinatorial dimer formation, with the dominant-negative isoform ERβcx providing a mechanism for ERα inhibition independent of ligand binding.\",\n      \"evidence\": \"cDNA screening, EMSA for homodimer/heterodimer DNA binding, GST pull-down and co-immunoprecipitation for ERα–ERβ interaction, ligand-binding assays for ERβcx\",\n      \"pmids\": [\"9636657\", \"9473491\", \"9671811\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo stoichiometry of ERα/ERβ dimers unknown\", \"Physiological relevance of ERβcx in tissues not established\", \"Crystal structure of ERα–ERβ heterodimer unavailable\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Domain-mapping experiments resolved how ERβ acts as a transdominant inhibitor of ERα: its N-terminal repressor domain and weak AF-1, combined with heterodimerization, reduce estradiol sensitivity and abolish tamoxifen's partial agonist activity through ERα.\",\n      \"evidence\": \"Domain deletion/chimeric receptor analysis, co-immunoprecipitation, chromatin binding assay, reporter assays in transfected cells\",\n      \"pmids\": [\"10579320\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the N-terminal repression function unresolved\", \"Chromatin-level mechanism of ligand-independent promoter occupancy not defined\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"In vivo loss-of-function in BERKO mice demonstrated that ERβ restrains ERα-driven uterine proliferation and gene induction (PR, VEGF, IGF-1), while parallel biochemical studies showed ERβ engages non-ERE pathways through direct Sp1 interaction and participates in non-genomic Src/Raf/ERK signaling.\",\n      \"evidence\": \"ERβ-knockout mouse uterine phenotyping, co-immunoprecipitation of ER–Sp1 complexes, GST pull-down of Src SH2/SH3 domains with ER, microinjection of dominant-negative Src blocking S-phase entry\",\n      \"pmids\": [\"10823946\", \"10681512\", \"11032808\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of genomic versus non-genomic ERβ signaling in specific tissues unclear\", \"Src interaction site on ERβ not mapped at residue level\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"ERβ was shown to be required for embryonic cortical neuronal migration and survival, extending its role beyond reproductive tissues and establishing a developmental neurobiology function.\",\n      \"evidence\": \"ERβ-knockout mice with BrdU birth-dating, TUNEL apoptosis assay, immunofluorescence of fragmented radial glia\",\n      \"pmids\": [\"12515851\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct ERβ transcriptional targets in developing brain not identified\", \"Whether mitochondrial ERβ contributes to neuronal survival not tested\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"The antiproliferative mechanism of ERβ was molecularly defined: ERβ represses cyclin D1, c-myc, and cyclin A while inducing p21 and p27, causing G2 arrest and inhibiting xenograft tumor growth, and was simultaneously found to reside predominantly in mitochondria in neurons and cardiomyocytes.\",\n      \"evidence\": \"Adenoviral ERβ expression in MCF-7 cells with flow cytometry and xenograft assays; subcellular fractionation, confocal colocalization with mitochondrial markers, and mass spectrometry of purified heart mitochondria\",\n      \"pmids\": [\"14729654\", \"14745018\", \"15024130\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mitochondrial ERβ target genes/functions not identified\", \"Whether mitochondrial localization is cell-type-restricted remains unclear\", \"Mechanism of mitochondrial import unknown\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Structural and functional analysis of ERβ isoforms established that a single functional helix 12 within a dimer is sufficient for transactivation, with ERβ1 serving as the obligatory active partner that is enhanced by heterodimerization with ligand-incompetent isoforms under estrogen stimulation.\",\n      \"evidence\": \"Molecular modeling, co-immunoprecipitation for isoform-specific dimerization, luciferase reporter assays, ligand-binding assays\",\n      \"pmids\": [\"16938840\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo isoform ratios in specific tissues not quantified\", \"No crystal structures of ERβ isoform heterodimers available\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"ERβ was shown to suppress NF-κB-mediated inflammation by blocking p65 nuclear translocation in macrophages, establishing a non-genomic anti-inflammatory mechanism distinct from its ERE-dependent transcriptional activity.\",\n      \"evidence\": \"Selective ERβ agonist ERB-041 in peritoneal macrophages, nuclear fractionation for NF-κB p65, ERK inhibitor controls\",\n      \"pmids\": [\"19447495\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular interaction between ERβ and NF-κB pathway components not demonstrated\", \"Not confirmed in genetic ERβ-knockout macrophages\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Genetic models (null and DBD-mutant rats) established that ESR2's canonical DNA-binding function in granulosa cells is required for follicle maturation, ovulation, and direct transcriptional regulation of Kiss1 through ERE binding and cooperation with ERK2-phosphorylated AP-1 factors.\",\n      \"evidence\": \"Esr2-null and Esr2-DBD mutant rat models, RNA-seq of granulosa cells, ChIP at Kiss1 regulatory regions, ERE mutagenesis/reporter assay, ERK2-ESR2 phosphorylation assay\",\n      \"pmids\": [\"29580824\", \"30277501\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full ERβ cistrome in granulosa cells not mapped\", \"Whether Kiss1 regulation by ERβ operates similarly in human granulosa cells not tested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"ESR2 was identified as the specific gatekeeper of the primordial follicle reserve, restraining AKT/mTOR-driven follicle activation through its transcriptional activity; complete gene deletion confirmed female subfertility progressing to infertility with age.\",\n      \"evidence\": \"Esr2-null and DBD-mutant rats with selective agonist/antagonist pharmacology, follicle counting, AKT/ERK/mTOR signaling Western blots; CRISPR/Cas9 all-exon deletion mice with fertility and histological assessment\",\n      \"pmids\": [\"32141511\", \"32703416\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets mediating AKT/mTOR suppression not identified\", \"Whether ESR2 acts cell-autonomously in oocytes versus granulosa cells not fully resolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"ESR2 variants (p.Asn181del, p.Leu426Arg) with gain-of-function transcriptional activity were identified in 46,XY DSD patients, implicating ESR2 in human sex development.\",\n      \"evidence\": \"Whole-exome sequencing of DSD patients, luciferase transactivation assays, protein structure analysis\",\n      \"pmids\": [\"29261182\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Small patient cohort without replication\", \"Mechanism by which gain-of-function ESR2 disrupts male sex development not defined\", \"No rescue or animal model recapitulating these specific variants\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the identity of direct ERβ transcriptional targets in mitochondria, the structural basis of ERα–ERβ heterodimer selectivity at specific promoters, the relative contributions of genomic versus non-genomic ERβ signaling in cardiovascular and neuroprotection, and whether the ESR2–AKT/mTOR axis in follicle maintenance operates through direct target gene regulation.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Mitochondrial ERβ targets/import mechanism unknown\", \"No ERα–ERβ heterodimer crystal structure\", \"Cell-autonomous versus paracrine ERβ action in ovarian follicle biology not dissected\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 2, 4, 5, 25]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 5, 10, 11, 13, 14, 24, 25, 28, 32]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [4, 5, 7, 16]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 5, 10, 21]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 5, 10, 11, 13, 24, 25]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [9, 20, 28, 33]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [13, 14]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [12, 24, 28, 29]},\n      {\"term_id\": \"R-HSA-1474165\", \"supporting_discovery_ids\": [24, 28, 29]}\n    ],\n    \"complexes\": [\n      \"ERα/ERβ heterodimer\",\n      \"ERβ homodimer\",\n      \"ER/Src/AR signaling complex\"\n    ],\n    \"partners\": [\n      \"ESR1\",\n      \"SRC\",\n      \"SP1\",\n      \"AHR\",\n      \"ARNT\",\n      \"EP300\",\n      \"NUPR1\",\n      \"AR\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}